Alirocumab vs Evolocumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Alirocumab · Praluent

Marketed by Regeneron Pharmaceuticals and partners

Approved in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Weak signal

NCT01507831 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 trial (ODYSSEY LONG TERM) gave alirocumab 150 mg or placebo every 2 weeks for 78 weeks, on top of maximum tolerated statins, to 2,341 patients at high cardiovascular risk. Its registered primary objective and primary outcome are long-term safety and tolerability, which have no formal efficacy test, so the registered primary has no met or missed result. The published paper reports the efficacy end point it pre-specified: LDL cholesterol fell 62 percentage points more with alirocumab than with placebo at week 24 (P<0.001). Sources: CT.gov posted results and the peer-reviewed paper (Robinson et al., N Engl J Med 2015). Its registered primary outcome on ClinicalTrials.gov is "Percentage of Participants Who Experienced Adverse Events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07477704 (registry estimate)

Reported efficacy

DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7) (met)

Result source: NCT03510884

Evolocumab · Repatha

Marketed by Amgen

Approved in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Partial signal

NCT01516879 · Phase 3 · completed

The study randomly assigned 905 participants to quadruple-blinded monthly evolocumab or placebo, with both groups continuing background lipid-lowering therapy. The primary endpoint was met, with a statistically significant difference in LDL-C change at week 52, but LDL-C is a surrogate laboratory endpoint rather than a clinical outcome.

Next expected readout: November 2026 · NCT06496243 (registry estimate)

Reported efficacy

Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08) (met)

Result source: NCT02392559

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlirocumabEvolocumab
LDL-C, % change-52.7% vs -0.3%−52.4 vs placebo300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144NCT01926782
165 other results
  • -58.8% vs -0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · primary NCT01926782
  • -45.7% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · primary NCT01617655
  • -48.2% vs -2.3% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · primary NCT01644175
  • -48.8% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · primary NCT01623115
  • -48.7% vs 2.8% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · primary NCT01709500
  • -48.2% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · primary NCT02585778
  • -51.7% vs 4.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · primary NCT02023879
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · primary NCT03156621
  • -43.8% vs -4.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · primary NCT02584504
  • -70.1% vs -4.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · primary NCT02584504
  • -50.2% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · primary NCT01926782
  • -51.6% vs -0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · primary NCT01926782
  • -51.8% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · primary NCT02585778
  • -57.1% vs 6.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · primary NCT02289963
  • -62.5% vs 1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · primary NCT02107898
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · primary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · primary NCT03510884
  • -50.6% vs -20.7% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · primary NCT01644188
  • -56% vs -20.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · primary NCT02715726
  • -47.2% vs -15.6% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · primary NCT01644474
  • -45% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · primary NCT01709513
  • -50.6% vs -15.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · primary NCT01730053
  • -36.3% vs -15.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · primary NCT01730053
  • -44.1% vs -5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · primary NCT01730040
  • -54% vs -5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · primary NCT01730040
  • -45.7% vs 8% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9462 · Phase 3 · secondary NCT01663402
  • -52.8% vs 8.2% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9451 · Phase 3 · secondary NCT01663402
  • -55.8% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9462 · Phase 3 · secondary NCT01663402
  • -58.3% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9451 · Phase 3 · secondary NCT01663402
  • -23.5% vs 16.4% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9462 · Phase 3 · secondary NCT01663402
  • -40.1% vs 14.6% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9451 · Phase 3 · secondary NCT01663402
  • -56.8% vs 4.4% 150 mg Q2W · wk 52 · n 1530 · Phase 3 · secondary NCT01507831
  • -59.9% vs 4.6% 150 mg Q2W · wk 52 · n 1523 · Phase 3 · secondary NCT01507831
  • -52.4% vs 3.6% 150 mg Q2W · wk 78 · n 1530 · Phase 3 · secondary NCT01507831
  • -58% vs 3.9% 150 mg Q2W · wk 78 · n 1523 · Phase 3 · secondary NCT01507831
  • -61% vs 0.8% 150 mg Q2W · wk 24 · n 1530 · Phase 3 · secondary NCT01507831
  • -62.8% vs 0.7% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -57.8% vs 3.5% 150 mg Q2W · wk 24 · n 1278 · Phase 3 · secondary NCT01507831
  • -63.3% vs 1.5% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -64.2% vs 1.4% 150 mg Q2W · wk 12 · n 1523 · Phase 3 · secondary NCT01507831
  • -59.4% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -62.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -58.4% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -55.3% vs 1.1% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -60% vs -0.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT01926782
  • -58% vs 1.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 302 · Phase 3 · secondary NCT01926782
  • -47.1% vs 9% 75 mg/Up to 150 mg Q2W · wk 52 · n 322 · Phase 3 · secondary NCT01623115
  • -48.1% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 52 · n 321 · Phase 3 · secondary NCT01623115
  • -50.3% vs 8.4% 75 mg/up to 150 mg · wk 52 · n 166 · Phase 3 · secondary NCT01709500
  • -40.3% vs 11.5% 75 mg/Up to 150 mg Q2W · wk 78 · n 322 · Phase 3 · secondary NCT01623115
  • -43.5% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -43.9% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 321 · Phase 3 · secondary NCT01623115
  • -42.1% vs -3% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42% vs -2.9% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42.5% vs 0.5% 75/150 mg Q2W · wk 52 · n 205 · Phase 3 · secondary NCT01644175
  • -40.9% vs -0.2% 150 mg Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -45.5% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -50.7% vs -0.8% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.3% vs 1.1% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -47.6% vs 1.7% 75/150 mg Q2W · wk 12 · n 204 · Phase 3 · secondary NCT01644175
  • -54.6% vs 5.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -43.4% vs -2.8% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -70.1% vs -2.8% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54.2% vs -3.7% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -3.7% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54% vs -2.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -2.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -41.7% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -44.8% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 57 · Phase 3 · secondary NCT02023879
  • -52.3% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · n 58 · Phase 3 · secondary NCT02023879
  • -55% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · n 57 · Phase 3 · secondary NCT02023879
  • -62.5% vs -3.6% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -64.6% vs -3.4% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -43.7% vs 14% 75 mg/Up to 150 mg Q2W · wk 78 · n 321 · Phase 3 · secondary NCT01623115
  • -49.3% vs 8.8% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -49.4% vs 2.7% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -55.3% vs 5.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -50.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 284 · Phase 3 · secondary NCT02585778
  • -43.3% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 277 · Phase 3 · secondary NCT02585778
  • -63.7% vs 1.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -43.8% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -44.2% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -48.8% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 284 · Phase 3 · secondary NCT02585778
  • -44.8% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 275 · Phase 3 · secondary NCT02585778
  • -42.3% vs 4% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -53.7% vs 1.6% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -54.6% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -55.1% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -53.8% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -64.2% vs -2.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -49.4% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -60.2% vs 6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -51.8% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -45.3% vs 1.1% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -53.9% vs -0.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -47.3% vs 1.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -50.8% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -51.5% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -49.4% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 49 · Phase 3 · secondary NCT02585778
  • -46.7% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 45 · Phase 3 · secondary NCT02585778
  • -57.9% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -58.4% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -64.8% vs -2.8% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -53.6% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -54.1% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -37.9% vs 1.2% 150 Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -49.5% vs -18.3% 75 /up to 150 mg Q2W · wk 52 · n 467 · Phase 3 · secondary NCT01644188
  • -51.8% vs -19.7% 75 /up to 150 mg Q2W · wk 52 · n 464 · Phase 3 · secondary NCT01644188
  • -52.4% vs -21.8% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -51.2% vs -21.8% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -52.4% vs -22.7% 75 /up to 150 mg Q2W · wk 12 · n 464 · Phase 3 · secondary NCT01644188
  • -44.2% vs -15.2% 75 /up to 150 mg Q2W · wk 104 · n 467 · Phase 3 · secondary NCT01644188
  • -48.9% vs -17% 75 /up to 150 mg Q2W · wk 104 · n 464 · Phase 3 · secondary NCT01644188
  • -58.7% vs -21.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -57.1% vs -22.2% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -58.1% vs -22.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 401 · Phase 3 · secondary NCT02715726
  • -48.1% vs -19.6% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -52.2% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -47.3% vs -15.2% 75 mg/ up to 150 mg · wk 24 · n 112 · Phase 3 · secondary NCT01709513
  • -47% vs -15.6% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -51.2% vs -18% 75 mg/ up to 150 mg · wk 12 · n 123 · Phase 3 · secondary NCT01709513
  • -53.5% vs -17% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -41.5% vs -17% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -48.6% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -57.8% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -49.6% vs -22.1% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -32.3% vs -22.1% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -52.6% vs -22.9% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -35.1% vs -22.9% 75 mg/up to 150 mg + 20 mg · wk 12 · n 51 · Phase 3 · secondary NCT01730053
  • -48.4% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -50.5% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -53.7% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 52 · Phase 3 · secondary NCT01730040
  • -50.9% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -66.2% vs -51.2% wk 4 · n 31 · Phase 3 · secondary NCT03415178
  • -73% vs 2% wk 2 · n 10 · Phase 4 · primary NCT02938949
  • -51.4% vs 2.8% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -50.4% vs 2.4% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -54.2% vs 3% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -49.6% vs 0.6% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -46.2% vs 4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -43.3% vs -0.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -41.7% vs -7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -63.9% vs -13.4% wk 36 · n 93 · Phase 4 · secondary NCT02984982
  • -64.5% vs -7.6% wk 12 · n 93 · Phase 4 · secondary NCT02984982
-50.1% vs 6.8%−57 vs placebowk 52 · n 599NCT01516879
57 other results
  • -44.5% vs -6.2% 420 mg QM · wk 24 · n 104 · Phase 3 · primary NCT02392559
  • -55.2% vs 1.7% wk 24 · n 295 · Phase 3 · primary NCT02833844
  • -61.6% vs 8.1% Q2W · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -58.2% vs 8.1% QM · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -61.8% vs 8.1% Q2W · wk 12 · n 109 · Phase 3 · primary NCT01763866
  • -58.7% vs 8.1% QM · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -60.1% vs 8.1% Q2W · wk 12 · n 113 · Phase 3 · primary NCT01763866
  • -59.4% vs 8.1% QM · wk 12 · n 115 · Phase 3 · primary NCT01763866
  • -58.9% vs 8.1% Q2W · wk 12 · n 111 · Phase 3 · primary NCT01763866
  • -52.4% vs 8.1% QM · wk 12 · n 112 · Phase 3 · primary NCT01763866
  • -65.9% vs 8.1% Q2W · wk 12 · n 112 · Phase 3 · primary NCT01763866
  • -57.0% vs 8.1% QM · wk 12 · n 115 · Phase 3 · primary NCT01763866
  • -57.0% vs -1.3% Q2W · wk 12 · n 153 · Phase 3 · primary NCT01763827
  • -56.1% vs -1.3% QM · wk 12 · n 153 · Phase 3 · primary NCT01763827
  • -62.3% vs 7.1% QM · wk 12 · n 332 · Phase 3 · primary NCT02662569
  • -54.3% vs -1.1% wk 12 · n 280 · Phase 3 · primary NCT02739984
  • -69.0% vs 4.9% QM · n 332 · Phase 3 · primary NCT02662569
  • -61.3% vs 5.5% Q2W · wk 12 · n 110 · Phase 3 · primary NCT01763918
  • -55.7% vs 5.5% QM · wk 12 · n 110 · Phase 3 · primary NCT01763918
  • -64.7% vs 7.1% Q2W · wk 12 · n 325 · Phase 3 · primary NCT02662569
  • -73.6% vs 1.4% Q2W · wk 12 · n 50 · Phase 3 · primary NCT01953328
  • -64.6% vs 1.4% QM · wk 12 · n 50 · Phase 3 · primary NCT01953328
  • -74.5% vs 1.4% Q2W · wk 12 · n 51 · Phase 3 · primary NCT01953328
  • -70.4% vs 1.4% QM · wk 12 · n 51 · Phase 3 · primary NCT01953328
  • -73.7% vs -0.4% Q2W · wk 11 · n 50 · Phase 3 · primary NCT01953328
  • -70.0% vs -0.4% QM · wk 11 · n 50 · Phase 3 · primary NCT01953328
  • -74.8% vs -0.4% Q2W · wk 11 · n 51 · Phase 3 · primary NCT01953328
  • -76.9% vs -0.4% QM · wk 11 · n 51 · Phase 3 · primary NCT01953328
  • -61.4% vs 7.5% Q2W · n 110 · Phase 3 · primary NCT01763866
  • -62.5% vs 7.5% QM · n 110 · Phase 3 · primary NCT01763866
  • -61.8% vs 7.5% Q2W · n 109 · Phase 3 · primary NCT01763866
  • -65.0% vs 7.5% QM · n 110 · Phase 3 · primary NCT01763866
  • -59.3% vs 7.5% Q2W · n 113 · Phase 3 · primary NCT01763866
  • -63.8% vs 7.5% QM · n 115 · Phase 3 · primary NCT01763866
  • -59.1% vs 7.5% Q2W · n 111 · Phase 3 · primary NCT01763866
  • -62.9% vs 7.5% QM · n 112 · Phase 3 · primary NCT01763866
  • -66.2% vs 7.5% Q2W · n 112 · Phase 3 · primary NCT01763866
  • -62.5% vs 7.5% QM · n 115 · Phase 3 · primary NCT01763866
  • -56.9% vs -1.4% Q2W · n 153 · Phase 3 · primary NCT01763827
  • -58.8% vs -1.4% QM · n 153 · Phase 3 · primary NCT01763827
  • -61.2% vs 2.3% Q2W · n 110 · Phase 3 · primary NCT01763918
  • -63.3% vs 2.3% QM · n 110 · Phase 3 · primary NCT01763918
  • -65.3% vs 4.9% Q2W · n 325 · Phase 3 · primary NCT02662569
  • -65.0% vs -0.8% n 280 · Phase 3 · primary NCT02739984
  • -23.1% vs 7.9% wk 12 · n 33 · Phase 2/3 · primary NCT01588496
  • -52.8% vs -16.7% wk 24 · n 145 · Phase 3 · primary NCT01984424
  • -56.1% vs -18.1% Q2W · wk 12 · n 103 · Phase 3 · primary NCT01763905
  • -52.6% vs -18.1% QM · wk 12 · n 102 · Phase 3 · primary NCT01763905
  • -54.5% vs -16.7% n 145 · Phase 3 · primary NCT01984424
  • -56.1% vs -19.2% Q2W · n 103 · Phase 3 · primary NCT01763905
  • -55.3% vs -19.2% QM · n 102 · Phase 3 · primary NCT01763905
  • -54.4% vs 3.2% wk 12 · n 599 · Phase 3 · secondary NCT01516879
  • -59.0% vs 1.6% 420 mg QM · wk 16 · n 62 · Phase 3 · secondary NCT02729025
  • -48.0% vs -5.9% 420 mg QM · n 104 · Phase 3 · secondary NCT02392559
  • -57.8% vs -0.7% wk 7.14 · n 18 · Phase 3 · secondary NCT02189837
  • -83.2% vs -0.7% wk 7.14 · n 17 · Phase 3 · secondary NCT02189837
  • -25.6% vs 4.2% n 33 · Phase 2/3 · secondary NCT01588496
Non-HDL-C, % change-51.6% vs 0.7%−52.3 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
87 other results
  • -53.1% vs 0.6% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -53.7% vs 0.9% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -43.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -49.7% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -48.9% vs 0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -52.6% vs 0.2% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -49.9% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -46.5% vs 0.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -42.8% vs 9.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -43.3% vs 9.4% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -38.4% vs 5.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -41.9% vs -6.2% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -41.7% vs -6.1% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -39.1% vs -1.6% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -40.9% vs -0.5% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -41.4% vs -6.9% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -37.4% vs 2.6% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -42.6% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -43.2% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -37.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -44.2% vs 4.8% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -46.7% vs 5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -36.2% vs -4.9% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -4.9% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -35.9% vs -3.5% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -3.5% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -34.9% vs 3% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -45.3% vs 4.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -46.9% vs 5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -45.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -47.2% vs 4.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -50.1% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -54.9% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -56% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -43.4% vs 3% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -47.3% vs 3.9% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -56.3% vs -1.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -35.7% vs 4.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -47.1% vs 2.8% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -41.6% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -37.9% vs 4.1% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -43.6% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -47.2% vs 0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -44.4% vs 0.2% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -45.8% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -37.4% vs 0.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -42.1% vs -19.2% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -43.7% vs -20.2% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -42.6% vs -20.6% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -47% vs -19.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -49.1% vs -20.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -47.4% vs -20.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -40.6% vs -15.1% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -42.5% vs -16.7% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -40.2% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -46.9% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -41.5% vs -15.8% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -42.7% vs -11.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -31.4% vs -11.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -45.7% vs -14.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -35.6% vs -14.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -36.7% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -47.6% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -40.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -50.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -41.2% vs -18% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -29.8% vs -18% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -40.6% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -42.3% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -37.3% vs -4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · primary NCT02642159
  • -44% vs 2.2% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.4% vs 0.7% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -41.1% vs 1.7% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.6% vs 1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -37% vs 2.5% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -35.5% vs -9.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -54.5% vs -14.1% wk 36 · n 93 · Phase 4 · secondary NCT02984982
-41.8% vs 8.4%−50.3 vs placebowk 52 · n 599NCT01516879
50 other results
  • -41.2% vs -6.1% 420 mg QM · wk 24 · n 104 · Phase 3 · secondary NCT02392559
  • -48.1% vs 2.9% wk 24 · n 296 · Phase 3 · secondary NCT02833844
  • -53.4% vs 7.9% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -52.2% vs 7.9% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -54.8% vs 7.9% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -50.0% vs 7.9% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -52.0% vs 7.9% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -51.6% vs 7.9% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -51.0% vs 7.9% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -46.4% vs 7.9% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -59.0% vs 7.9% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -51.0% vs 7.9% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -50.1% vs 1.5% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -49.7% vs 1.5% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -52.9% vs 5.9% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -59.1% vs 4.3% QM · n 332 · Phase 3 · secondary NCT02662569
  • -56.2% vs 5.3% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -49.7% vs 5.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -55.8% vs 5.9% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -46.9% vs -0.6% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -67.8% vs -0.1% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -58.0% vs -0.1% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -68.9% vs -0.1% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -63.3% vs -0.1% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -68.5% vs -1.6% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -61.7% vs -1.6% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -69.7% vs -1.6% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -69.1% vs -1.6% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -53.5% vs 7.0% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -56.1% vs 7.0% QM · n 110 · Phase 3 · secondary NCT01763866
  • -54.4% vs 7.0% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -56.3% vs 7.0% QM · n 110 · Phase 3 · secondary NCT01763866
  • -52.6% vs 7.0% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -55.5% vs 7.0% QM · n 115 · Phase 3 · secondary NCT01763866
  • -52.1% vs 7.0% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -55.7% vs 7.0% QM · n 112 · Phase 3 · secondary NCT01763866
  • -59.3% vs 7.0% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -56.0% vs 7.0% QM · n 115 · Phase 3 · secondary NCT01763866
  • -50.2% vs 1.3% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -52.0% vs 1.3% QM · n 153 · Phase 3 · secondary NCT01763827
  • -55.8% vs 2.7% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -57.3% vs 2.7% QM · n 110 · Phase 3 · secondary NCT01763918
  • -56.6% vs 4.3% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -56.6% vs -0.1% n 280 · Phase 3 · secondary NCT02739984
  • -45.7% vs -14.6% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -48.6% vs -16.5% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -46.1% vs -16.5% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -47.4% vs -14.4% n 145 · Phase 3 · secondary NCT01984424
  • -48.7% vs -17.2% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -49.1% vs -17.2% QM · n 102 · Phase 3 · secondary NCT01763905
ApoB, % change-52.8% vs 1.2%−54 vs placebo150 mg Q2W · wk 24 · n 1468NCT01507831
86 other results
  • -54.3% vs 1.2% 150 mg Q2W · wk 24 · n 1444 · Phase 3 · secondary NCT01507831
  • -55.5% vs 0.5% 150 mg Q2W · wk 12 · n 1468 · Phase 3 · secondary NCT01507831
  • -40.2% vs -0.7% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01926782
  • -45.1% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 292 · Phase 3 · secondary NCT01926782
  • -44.8% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -47.2% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 286 · Phase 3 · secondary NCT01926782
  • -46.4% vs -2.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 138 · Phase 3 · secondary NCT01926782
  • -41.2% vs 3.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 292 · Phase 3 · secondary NCT01926782
  • -41.1% vs 4.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 309 · Phase 3 · secondary NCT01623115
  • -41.4% vs 4.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01623115
  • -34.5% vs 3.1% 75 mg/Up to 150 mg Q2W · wk 12 · n 309 · Phase 3 · secondary NCT01623115
  • -39% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -38.9% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -36.7% vs -0.9% 75/150 mg Q2W · wk 24 · n 185 · Phase 3 · secondary NCT01644175
  • -37.9% vs -0.4% 75/150 mg Q2W · wk 24 · n 181 · Phase 3 · secondary NCT01644175
  • -39.2% vs -9% 150 mg Q2W · wk 12 · n 69 · Phase 3 · secondary NCT01617655
  • -34.8% vs 3.4% 75/150 mg Q2W · wk 12 · n 185 · Phase 3 · secondary NCT01644175
  • -42.8% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 163 · Phase 3 · secondary NCT01709500
  • -43.2% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 162 · Phase 3 · secondary NCT01709500
  • -33.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 279 · Phase 3 · secondary NCT02585778
  • -38.9% vs 7.5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -40.9% vs 7.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 54 · Phase 3 · secondary NCT02023879
  • -32.2% vs -6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -57.9% vs -6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.8% vs -4.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -58% vs -4.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.3% vs 7% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -39.7% vs 7.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -41.2% vs 7.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -39.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -42.3% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 96 · Phase 3 · secondary NCT02289963
  • -45.4% vs 3.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 95 · Phase 3 · secondary NCT02289963
  • -55% vs -1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT02107898
  • -55.9% vs -2.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 140 · Phase 3 · secondary NCT02107898
  • -38.4% vs 7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 112 · Phase 3 · secondary NCT02023879
  • -40.9% vs 5.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 96 · Phase 3 · secondary NCT02289963
  • -54.6% vs -3.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT02107898
  • -33.8% vs 1.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -42.8% vs 1.2% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -36.7% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -35.4% vs -0.9% 75 mg/up to 150 mg · wk 12 · n 163 · Phase 3 · secondary NCT01709500
  • -39% vs -0.7% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 34 · Phase 3 · secondary NCT01926782
  • -42% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -38.3% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 74 · Phase 3 · secondary NCT01926782
  • -40.8% vs -2.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 34 · Phase 3 · secondary NCT01926782
  • -33% vs 3.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -40.7% vs -18.3% 75 /up to 150 mg Q2W · wk 24 · n 452 · Phase 3 · secondary NCT01644188
  • -42.1% vs -19.1% 75 /up to 150 mg Q2W · wk 24 · n 442 · Phase 3 · secondary NCT01644188
  • -39.7% vs -17.2% 75 /up to 150 mg Q2W · wk 12 · n 452 · Phase 3 · secondary NCT01644188
  • -43.5% vs -16.2% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 398 · Phase 3 · secondary NCT02715726
  • -45.2% vs -17.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 392 · Phase 3 · secondary NCT02715726
  • -43% vs -16.5% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 398 · Phase 3 · secondary NCT02715726
  • -36.7% vs -11% 75/Up to 150 mg Q2W · wk 24 · n 48 · Phase 3 · secondary NCT01644474
  • -37.3% vs -11.7% 75/Up to 150 mg Q2W · wk 12 · n 48 · Phase 3 · secondary NCT01644474
  • -36.3% vs -11.2% 75 mg/ up to 150 mg · wk 24 · n 122 · Phase 3 · secondary NCT01709513
  • -42.6% vs -14.4% 75 mg/ up to 150 mg · wk 24 · n 109 · Phase 3 · secondary NCT01709513
  • -36.1% vs -11.6% 75 mg/ up to 150 mg · wk 12 · n 122 · Phase 3 · secondary NCT01709513
  • -36.5% vs -9.8% 75 mg/up to 150 mg + 10 mg · wk 24 · n 44 · Phase 3 · secondary NCT01730053
  • -28.3% vs -9.8% 75 mg/up to 150 mg + 20 mg · wk 24 · n 49 · Phase 3 · secondary NCT01730053
  • -39.5% vs -12.7% 75 mg/up to 150 mg + 10 mg · wk 24 · n 43 · Phase 3 · secondary NCT01730053
  • -30.4% vs -12.7% 75 mg/up to 150 mg + 20 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -33.7% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730040
  • -41.9% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 42 · Phase 3 · secondary NCT01730040
  • -37.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 50 · Phase 3 · secondary NCT01730040
  • -42.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 41 · Phase 3 · secondary NCT01730040
  • -36.1% vs -13.7% 75 mg/up to 150 mg + 10 mg · wk 12 · n 44 · Phase 3 · secondary NCT01730053
  • -29% vs -13.7% 75 mg/up to 150 mg + 20 mg · wk 12 · n 49 · Phase 3 · secondary NCT01730053
  • -38.4% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730040
  • -36.2% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 42 · Phase 3 · secondary NCT01730040
  • -40.9% vs 2.1% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -36.7% vs 0.8% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -39% vs 1.1% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -39.1% vs 0.2% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -36.4% vs 1.4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -33.8% vs -1.6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.1% vs -16.6% wk 36 · n 92 · Phase 4 · secondary NCT02984982
-41.3% vs 2.9%−44.2 vs placebowk 52 · n 599NCT01516879
53 other results
  • -34.9% vs -2.4% 420 mg QM · wk 24 · n 104 · Phase 3 · secondary NCT02392559
  • -45.1% vs 2.6% wk 24 · n 302 · Phase 3 · secondary NCT02833844
  • -48.3% vs 3.3% 420 mg QM · wk 16 · n 63 · Phase 3 · secondary NCT02729025
  • -50.9% vs 6.3% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -47.1% vs 6.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -49.8% vs 6.3% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -46.5% vs 6.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -50.1% vs 6.3% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -48.6% vs 6.3% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -45.6% vs 6.3% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -43.7% vs 6.3% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -56.0% vs 6.3% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -49.2% vs 6.3% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -47.2% vs 1.8% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -46.6% vs 1.8% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -49.7% vs 3.2% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -56.4% vs 2.0% QM · n 332 · Phase 3 · secondary NCT02662569
  • -49.8% vs 4.6% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -44.8% vs 4.6% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -53.9% vs 3.2% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -40.3% vs 1.8% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -64.8% vs -2.5% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -54.8% vs -2.5% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -62.8% vs -2.5% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -64.4% vs -4.3% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -51.0% vs 5.1% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -51.4% vs 5.1% QM · n 110 · Phase 3 · secondary NCT01763866
  • -49.1% vs 5.1% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -53.3% vs 5.1% QM · n 110 · Phase 3 · secondary NCT01763866
  • -49.8% vs 5.1% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -53.6% vs 5.1% QM · n 115 · Phase 3 · secondary NCT01763866
  • -47.1% vs 5.1% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -53.0% vs 5.1% QM · n 112 · Phase 3 · secondary NCT01763866
  • -55.6% vs 5.1% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -54.4% vs 5.1% QM · n 115 · Phase 3 · secondary NCT01763866
  • -47.0% vs 1.5% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -49.4% vs 1.5% QM · n 153 · Phase 3 · secondary NCT01763827
  • -49.6% vs 2.2% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -52.8% vs 2.2% QM · n 110 · Phase 3 · secondary NCT01763918
  • -55.0% vs 2.0% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -50.2% vs 2.3% n 280 · Phase 3 · secondary NCT02739984
  • -19.2% vs 4.0% wk 12 · n 33 · Phase 2/3 · secondary NCT01588496
  • -58.0% vs -2.5% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -64.8% vs -4.3% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -58.5% vs -4.3% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -64.2% vs -4.3% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -20.2% vs 2.6% n 33 · Phase 2/3 · secondary NCT01588496
  • -43.5% vs -11.7% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -45.8% vs -12.9% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -43.1% vs -12.9% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -45.3% vs -11.4% n 145 · Phase 3 · secondary NCT01984424
  • -45.9% vs -13.7% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -46.0% vs -13.7% QM · n 102 · Phase 3 · secondary NCT01763905
Lp(a), % change-29.3% vs -3.7%−25.6 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
64 other results
  • -28.2% vs -3.1% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -21.3% vs 6.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -19.3% vs 9.8% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -28.9% vs -5.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -19.6% vs 7% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -23.5% vs -8.7% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -20.5% vs -5.9% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -23.2% vs -1.5% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -19.7% vs 0% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -25.2% vs -7.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -15.5% vs 4.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -31.7% vs 1.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -49.6% vs 1.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -5.7% vs 2.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -30.3% vs -10% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -21.8% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -19% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -21.2% vs -3.9% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -24.7% vs -5.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -6.1% vs -1.2% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -18.1% vs -4% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -14% vs 6.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -16.9% vs 9.8% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -23% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -35.9% vs -2.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -39.5% vs 2.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -26.9% vs -5.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -12.4% vs 7% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -16.5% vs 2.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -33.6% vs -1.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -41.9% vs -0.5% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16.0% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -27.8% vs -6.1% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -22.1% vs 1.1% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -30.3% vs 4.0% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -30.1% vs 6.3% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -16.7% vs -12.3% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -17.2% vs -14.2% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -25.9% vs -7.3% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -21.7% vs -4.5% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -27.9% vs -5.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -22.7% vs -5.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -23.6% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -30.8% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -20.7% vs 3.5% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -16% vs 3.5% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -24% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -27.9% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -24.7% vs -0.5% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -22.4% vs -3.3% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -24.3% vs -1.4% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -25.1% vs -1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -17.7% vs 4.8% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -23.7% vs 3.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.8% vs -17.2% wk 36 · n 92 · Phase 4 · secondary NCT02984982
-16.4% vs 10.3%−26.8 vs placebowk 24 · n 302NCT02833844
52 other results
  • -27.7% vs -5.4% wk 52 · n 599 · Phase 3 · secondary NCT01516879
  • -12.8% vs 1.1% 420 mg QM · wk 16 · n 63 · Phase 3 · secondary NCT02729025
  • -25.9% vs 11.4% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -20.3% vs 11.4% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -24.6% vs 11.4% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -24.7% vs 11.4% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -25.1% vs 11.4% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -20.9% vs 11.4% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -26.1% vs 11.4% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -22.0% vs 11.4% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -38.1% vs 11.4% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -29.2% vs 11.4% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -20.4% vs 0% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -17.8% vs 0% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -25.2% vs 7.4% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -42.3% vs 16.9% QM · n 332 · Phase 3 · secondary NCT02662569
  • -22.9% vs 6.7% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -21.6% vs 6.7% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -35.9% vs 26.5% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -37.9% vs 26.5% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -45.7% vs 10.8% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -41.7% vs 10.8% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -41.9% vs 10.8% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -45.7% vs 10.8% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -45.0% vs 6.5% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -49.5% vs 6.5% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -26.0% vs 11.4% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -22.6% vs 11.4% QM · n 110 · Phase 3 · secondary NCT01763866
  • -24.0% vs 11.4% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -27.5% vs 11.4% QM · n 110 · Phase 3 · secondary NCT01763866
  • -24.3% vs 11.4% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -23.2% vs 11.4% QM · n 115 · Phase 3 · secondary NCT01763866
  • -25.0% vs 11.4% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -25.9% vs 11.4% QM · n 112 · Phase 3 · secondary NCT01763866
  • -38.6% vs 11.4% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -32.2% vs 11.4% QM · n 115 · Phase 3 · secondary NCT01763866
  • -18.4% vs 0% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -19.2% vs 0% QM · n 153 · Phase 3 · secondary NCT01763827
  • -24.0% vs 5.3% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -25.6% vs 5.3% QM · n 110 · Phase 3 · secondary NCT01763918
  • -38.6% vs 16.9% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -30.9% vs 9.6% n 280 · Phase 3 · secondary NCT02739984
  • -9.4% vs 2.4% wk 12 · n 33 · Phase 2/3 · secondary NCT01588496
  • -46.0% vs 6.5% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -43.0% vs 6.5% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -12.7% vs -1.4% n 33 · Phase 2/3 · secondary NCT01588496
  • -21.1% vs 0.2% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -27.0% vs -1.7% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -22.1% vs -1.7% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -22.7% vs -1.6% n 145 · Phase 3 · secondary NCT01984424
  • -26.2% vs -2.3% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -23.7% vs -2.3% QM · n 102 · Phase 3 · secondary NCT01763905
3-point MACE (% with event)—Not posted · NCT047905137.9% vs 9.9%−2 vs placebowk 156 · n 13784NCT01764633
5 other results
  • 6.7% vs 8.3% wk 130 · n 13784 · Phase 3 · secondary NCT01764633
  • 5.5% vs 6.8% wk 104 · n 13784 · Phase 3 · secondary NCT01764633
  • 4.3% vs 5.2% wk 78 · n 13784 · Phase 3 · secondary NCT01764633
  • 3.1% vs 3.7% wk 52 · n 13784 · Phase 3 · secondary NCT01764633
  • 1.6% vs 1.9% wk 26 · n 13784 · Phase 3 · secondary NCT01764633

LDL-C, % change

Alirocumab
-52.7% vs -0.3%−52.4 vs placebo300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144NCT01926782
165 other results
  • -58.8% vs -0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · primary NCT01926782
  • -45.7% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · primary NCT01617655
  • -48.2% vs -2.3% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · primary NCT01644175
  • -48.8% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · primary NCT01623115
  • -48.7% vs 2.8% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · primary NCT01709500
  • -48.2% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · primary NCT02585778
  • -51.7% vs 4.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · primary NCT02023879
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · primary NCT03156621
  • -43.8% vs -4.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · primary NCT02584504
  • -70.1% vs -4.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · primary NCT02584504
  • -50.2% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · primary NCT01926782
  • -51.6% vs -0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · primary NCT01926782
  • -51.8% vs 0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · primary NCT02585778
  • -57.1% vs 6.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · primary NCT02289963
  • -62.5% vs 1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · primary NCT02107898
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · primary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · primary NCT03510884
  • -50.6% vs -20.7% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · primary NCT01644188
  • -56% vs -20.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · primary NCT02715726
  • -47.2% vs -15.6% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · primary NCT01644474
  • -45% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · primary NCT01709513
  • -50.6% vs -15.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · primary NCT01730053
  • -36.3% vs -15.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · primary NCT01730053
  • -44.1% vs -5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · primary NCT01730040
  • -54% vs -5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · primary NCT01730040
  • -45.7% vs 8% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9462 · Phase 3 · secondary NCT01663402
  • -52.8% vs 8.2% 75 mg Q2W/Up to 150 mg Q2W · wk 52 · n 9451 · Phase 3 · secondary NCT01663402
  • -55.8% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9462 · Phase 3 · secondary NCT01663402
  • -58.3% vs 4.4% 75 mg Q2W/Up to 150 mg Q2W · wk 17.33 · n 9451 · Phase 3 · secondary NCT01663402
  • -23.5% vs 16.4% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9462 · Phase 3 · secondary NCT01663402
  • -40.1% vs 14.6% 75 mg Q2W/Up to 150 mg Q2W · wk 208 · n 9451 · Phase 3 · secondary NCT01663402
  • -56.8% vs 4.4% 150 mg Q2W · wk 52 · n 1530 · Phase 3 · secondary NCT01507831
  • -59.9% vs 4.6% 150 mg Q2W · wk 52 · n 1523 · Phase 3 · secondary NCT01507831
  • -52.4% vs 3.6% 150 mg Q2W · wk 78 · n 1530 · Phase 3 · secondary NCT01507831
  • -58% vs 3.9% 150 mg Q2W · wk 78 · n 1523 · Phase 3 · secondary NCT01507831
  • -61% vs 0.8% 150 mg Q2W · wk 24 · n 1530 · Phase 3 · secondary NCT01507831
  • -62.8% vs 0.7% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -57.8% vs 3.5% 150 mg Q2W · wk 24 · n 1278 · Phase 3 · secondary NCT01507831
  • -63.3% vs 1.5% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -64.2% vs 1.4% 150 mg Q2W · wk 12 · n 1523 · Phase 3 · secondary NCT01507831
  • -59.4% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -62.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -58.4% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -55.3% vs 1.1% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -60% vs -0.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT01926782
  • -58% vs 1.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 302 · Phase 3 · secondary NCT01926782
  • -47.1% vs 9% 75 mg/Up to 150 mg Q2W · wk 52 · n 322 · Phase 3 · secondary NCT01623115
  • -48.1% vs 9.1% 75 mg/Up to 150 mg Q2W · wk 52 · n 321 · Phase 3 · secondary NCT01623115
  • -50.3% vs 8.4% 75 mg/up to 150 mg · wk 52 · n 166 · Phase 3 · secondary NCT01709500
  • -40.3% vs 11.5% 75 mg/Up to 150 mg Q2W · wk 78 · n 322 · Phase 3 · secondary NCT01623115
  • -43.5% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -43.9% vs 5.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 321 · Phase 3 · secondary NCT01623115
  • -42.1% vs -3% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42% vs -2.9% 150 mg Q2W · wk 52 · n 71 · Phase 3 · secondary NCT01617655
  • -42.5% vs 0.5% 75/150 mg Q2W · wk 52 · n 205 · Phase 3 · secondary NCT01644175
  • -40.9% vs -0.2% 150 mg Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -45.5% vs -6.6% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -50.7% vs -0.8% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.9% vs -6.6% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -46.3% vs 1.1% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -47.6% vs 1.7% 75/150 mg Q2W · wk 12 · n 204 · Phase 3 · secondary NCT01644175
  • -54.6% vs 5.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -43.4% vs -2.8% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -70.1% vs -2.8% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54.2% vs -3.7% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -3.7% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -54% vs -2.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -69.9% vs -2.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -41.7% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -44.8% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 57 · Phase 3 · secondary NCT02023879
  • -52.3% vs 3.2% 150 mg Q4W/Up to 150 mg Q2W · n 58 · Phase 3 · secondary NCT02023879
  • -55% vs 3.6% 150 mg Q4W/Up to 150 mg Q2W · n 57 · Phase 3 · secondary NCT02023879
  • -62.5% vs -3.6% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -64.6% vs -3.4% 75 mg/Up to 150 mg Q2W · wk 52 · n 143 · Phase 3 · secondary NCT02107898
  • -43.7% vs 14% 75 mg/Up to 150 mg Q2W · wk 78 · n 321 · Phase 3 · secondary NCT01623115
  • -49.3% vs 8.8% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -49.4% vs 2.7% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -55.3% vs 5.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -50.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 284 · Phase 3 · secondary NCT02585778
  • -43.3% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 277 · Phase 3 · secondary NCT02585778
  • -63.7% vs 1.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -43.8% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -44.2% vs 4.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -48.8% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 284 · Phase 3 · secondary NCT02585778
  • -44.8% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 275 · Phase 3 · secondary NCT02585778
  • -42.3% vs 4% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -26.9% vs 8.6% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -53.7% vs 1.6% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -54.6% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -55.1% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -53.8% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -64.2% vs -2.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -49.4% vs 2.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -60.2% vs 6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -51.8% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -45.3% vs 1.1% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -53.9% vs -0.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -47.3% vs 1.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -50.8% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -51.5% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -49.4% vs 1.4% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 49 · Phase 3 · secondary NCT02585778
  • -46.7% vs -0.8% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 45 · Phase 3 · secondary NCT02585778
  • -57.9% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -58.4% vs 4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -64.8% vs -2.8% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -53.6% vs 3.2% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -54.1% vs 3.6% 75 mg Q2W/Up to 150 mg Q2W · n 115 · Phase 3 · secondary NCT02023879
  • -37.9% vs 1.2% 150 Q2W · wk 78 · n 71 · Phase 3 · secondary NCT01617655
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33.6% vs -4.4% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -38.2% vs -4.4% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -34.8% vs 2.3% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -39.2% vs 2.3% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -35.4% vs -3.8% Q2W · wk 8 · n 49 · Phase 3 · secondary NCT03510884
  • -42% vs -3.8% Q4W · wk 8 · n 50 · Phase 3 · secondary NCT03510884
  • -49.5% vs -18.3% 75 /up to 150 mg Q2W · wk 52 · n 467 · Phase 3 · secondary NCT01644188
  • -51.8% vs -19.7% 75 /up to 150 mg Q2W · wk 52 · n 464 · Phase 3 · secondary NCT01644188
  • -52.4% vs -21.8% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -51.2% vs -21.8% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -52.4% vs -22.7% 75 /up to 150 mg Q2W · wk 12 · n 464 · Phase 3 · secondary NCT01644188
  • -44.2% vs -15.2% 75 /up to 150 mg Q2W · wk 104 · n 467 · Phase 3 · secondary NCT01644188
  • -48.9% vs -17% 75 /up to 150 mg Q2W · wk 104 · n 464 · Phase 3 · secondary NCT01644188
  • -58.7% vs -21.3% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -57.1% vs -22.2% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -58.1% vs -22.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 401 · Phase 3 · secondary NCT02715726
  • -48.1% vs -19.6% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -52.2% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -47.3% vs -15.2% 75 mg/ up to 150 mg · wk 24 · n 112 · Phase 3 · secondary NCT01709513
  • -47% vs -15.6% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -51.2% vs -18% 75 mg/ up to 150 mg · wk 12 · n 123 · Phase 3 · secondary NCT01709513
  • -53.5% vs -17% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -41.5% vs -17% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -48.6% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -57.8% vs -6.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -49.6% vs -22.1% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -32.3% vs -22.1% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -52.6% vs -22.9% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -35.1% vs -22.9% 75 mg/up to 150 mg + 20 mg · wk 12 · n 51 · Phase 3 · secondary NCT01730053
  • -48.4% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -50.5% vs -8.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -53.7% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 52 · Phase 3 · secondary NCT01730040
  • -50.9% vs -9.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -66.2% vs -51.2% wk 4 · n 31 · Phase 3 · secondary NCT03415178
  • -73% vs 2% wk 2 · n 10 · Phase 4 · primary NCT02938949
  • -51.4% vs 2.8% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -50.4% vs 2.4% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -54.2% vs 3% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -49.6% vs 0.6% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -46.2% vs 4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -43.3% vs -0.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -41.7% vs -7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -63.9% vs -13.4% wk 36 · n 93 · Phase 4 · secondary NCT02984982
  • -64.5% vs -7.6% wk 12 · n 93 · Phase 4 · secondary NCT02984982
Evolocumab
-50.1% vs 6.8%−57 vs placebowk 52 · n 599NCT01516879
57 other results
  • -44.5% vs -6.2% 420 mg QM · wk 24 · n 104 · Phase 3 · primary NCT02392559
  • -55.2% vs 1.7% wk 24 · n 295 · Phase 3 · primary NCT02833844
  • -61.6% vs 8.1% Q2W · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -58.2% vs 8.1% QM · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -61.8% vs 8.1% Q2W · wk 12 · n 109 · Phase 3 · primary NCT01763866
  • -58.7% vs 8.1% QM · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -60.1% vs 8.1% Q2W · wk 12 · n 113 · Phase 3 · primary NCT01763866
  • -59.4% vs 8.1% QM · wk 12 · n 115 · Phase 3 · primary NCT01763866
  • -58.9% vs 8.1% Q2W · wk 12 · n 111 · Phase 3 · primary NCT01763866
  • -52.4% vs 8.1% QM · wk 12 · n 112 · Phase 3 · primary NCT01763866
  • -65.9% vs 8.1% Q2W · wk 12 · n 112 · Phase 3 · primary NCT01763866
  • -57.0% vs 8.1% QM · wk 12 · n 115 · Phase 3 · primary NCT01763866
  • -57.0% vs -1.3% Q2W · wk 12 · n 153 · Phase 3 · primary NCT01763827
  • -56.1% vs -1.3% QM · wk 12 · n 153 · Phase 3 · primary NCT01763827
  • -62.3% vs 7.1% QM · wk 12 · n 332 · Phase 3 · primary NCT02662569
  • -54.3% vs -1.1% wk 12 · n 280 · Phase 3 · primary NCT02739984
  • -69.0% vs 4.9% QM · n 332 · Phase 3 · primary NCT02662569
  • -61.3% vs 5.5% Q2W · wk 12 · n 110 · Phase 3 · primary NCT01763918
  • -55.7% vs 5.5% QM · wk 12 · n 110 · Phase 3 · primary NCT01763918
  • -64.7% vs 7.1% Q2W · wk 12 · n 325 · Phase 3 · primary NCT02662569
  • -73.6% vs 1.4% Q2W · wk 12 · n 50 · Phase 3 · primary NCT01953328
  • -64.6% vs 1.4% QM · wk 12 · n 50 · Phase 3 · primary NCT01953328
  • -74.5% vs 1.4% Q2W · wk 12 · n 51 · Phase 3 · primary NCT01953328
  • -70.4% vs 1.4% QM · wk 12 · n 51 · Phase 3 · primary NCT01953328
  • -73.7% vs -0.4% Q2W · wk 11 · n 50 · Phase 3 · primary NCT01953328
  • -70.0% vs -0.4% QM · wk 11 · n 50 · Phase 3 · primary NCT01953328
  • -74.8% vs -0.4% Q2W · wk 11 · n 51 · Phase 3 · primary NCT01953328
  • -76.9% vs -0.4% QM · wk 11 · n 51 · Phase 3 · primary NCT01953328
  • -61.4% vs 7.5% Q2W · n 110 · Phase 3 · primary NCT01763866
  • -62.5% vs 7.5% QM · n 110 · Phase 3 · primary NCT01763866
  • -61.8% vs 7.5% Q2W · n 109 · Phase 3 · primary NCT01763866
  • -65.0% vs 7.5% QM · n 110 · Phase 3 · primary NCT01763866
  • -59.3% vs 7.5% Q2W · n 113 · Phase 3 · primary NCT01763866
  • -63.8% vs 7.5% QM · n 115 · Phase 3 · primary NCT01763866
  • -59.1% vs 7.5% Q2W · n 111 · Phase 3 · primary NCT01763866
  • -62.9% vs 7.5% QM · n 112 · Phase 3 · primary NCT01763866
  • -66.2% vs 7.5% Q2W · n 112 · Phase 3 · primary NCT01763866
  • -62.5% vs 7.5% QM · n 115 · Phase 3 · primary NCT01763866
  • -56.9% vs -1.4% Q2W · n 153 · Phase 3 · primary NCT01763827
  • -58.8% vs -1.4% QM · n 153 · Phase 3 · primary NCT01763827
  • -61.2% vs 2.3% Q2W · n 110 · Phase 3 · primary NCT01763918
  • -63.3% vs 2.3% QM · n 110 · Phase 3 · primary NCT01763918
  • -65.3% vs 4.9% Q2W · n 325 · Phase 3 · primary NCT02662569
  • -65.0% vs -0.8% n 280 · Phase 3 · primary NCT02739984
  • -23.1% vs 7.9% wk 12 · n 33 · Phase 2/3 · primary NCT01588496
  • -52.8% vs -16.7% wk 24 · n 145 · Phase 3 · primary NCT01984424
  • -56.1% vs -18.1% Q2W · wk 12 · n 103 · Phase 3 · primary NCT01763905
  • -52.6% vs -18.1% QM · wk 12 · n 102 · Phase 3 · primary NCT01763905
  • -54.5% vs -16.7% n 145 · Phase 3 · primary NCT01984424
  • -56.1% vs -19.2% Q2W · n 103 · Phase 3 · primary NCT01763905
  • -55.3% vs -19.2% QM · n 102 · Phase 3 · primary NCT01763905
  • -54.4% vs 3.2% wk 12 · n 599 · Phase 3 · secondary NCT01516879
  • -59.0% vs 1.6% 420 mg QM · wk 16 · n 62 · Phase 3 · secondary NCT02729025
  • -48.0% vs -5.9% 420 mg QM · n 104 · Phase 3 · secondary NCT02392559
  • -57.8% vs -0.7% wk 7.14 · n 18 · Phase 3 · secondary NCT02189837
  • -83.2% vs -0.7% wk 7.14 · n 17 · Phase 3 · secondary NCT02189837
  • -25.6% vs 4.2% n 33 · Phase 2/3 · secondary NCT01588496

Non-HDL-C, % change

Alirocumab
-51.6% vs 0.7%−52.3 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
87 other results
  • -53.1% vs 0.6% 150 mg Q2W · wk 24 · n 1523 · Phase 3 · secondary NCT01507831
  • -53.7% vs 0.9% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -43.3% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -49.7% vs 0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -48.9% vs 0.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -52.6% vs 0.2% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 302 · Phase 3 · secondary NCT01926782
  • -49.9% vs -0.4% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -46.5% vs 0.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -42.8% vs 9.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -43.3% vs 9.4% 75 mg/Up to 150 mg Q2W · wk 24 · n 321 · Phase 3 · secondary NCT01623115
  • -38.4% vs 5.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -41.9% vs -6.2% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -41.7% vs -6.1% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -39.1% vs -1.6% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -40.9% vs -0.5% 75/150 mg Q2W · wk 24 · n 204 · Phase 3 · secondary NCT01644175
  • -41.4% vs -6.9% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -37.4% vs 2.6% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -42.6% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -43.2% vs 3.1% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -37.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -44.2% vs 4.8% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -46.7% vs 5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 57 · Phase 3 · secondary NCT02023879
  • -36.2% vs -4.9% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -4.9% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -35.9% vs -3.5% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -61.1% vs -3.5% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -34.9% vs 3% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -45.3% vs 4.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -46.9% vs 5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -45.9% vs 0.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -47.2% vs 4.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -50.1% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -54.9% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -56% vs 2.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -43.4% vs 3% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -47.3% vs 3.9% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -56.3% vs -1.7% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -35.7% vs 4.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -24.8% vs 8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -47.1% vs 2.8% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -41.6% vs 0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -37.9% vs 4.1% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -43.6% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -47.2% vs 0.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -44.4% vs 0.2% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -45.8% vs -0.4% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -37.4% vs 0.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -31% vs -3.7% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -35.6% vs -3.7% Q4W · wk 24 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -33% vs 2.8% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -34.7% vs 2.8% Q4W · wk 12 · n 50 · Phase 3 · secondary NCT03510884
  • -42.1% vs -19.2% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -43.7% vs -20.2% 75 /up to 150 mg Q2W · wk 24 · n 464 · Phase 3 · secondary NCT01644188
  • -42.6% vs -20.6% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -47% vs -19.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -49.1% vs -20.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 401 · Phase 3 · secondary NCT02715726
  • -47.4% vs -20.7% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -40.6% vs -15.1% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -42.5% vs -16.7% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -40.2% vs -14.6% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -46.9% vs -17.1% 75 mg/ up to 150 mg · wk 24 · n 123 · Phase 3 · secondary NCT01709513
  • -41.5% vs -15.8% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -42.7% vs -11.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -31.4% vs -11.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -45.7% vs -14.9% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -35.6% vs -14.9% 75 mg/up to 150 mg + 20 mg · wk 24 · n 51 · Phase 3 · secondary NCT01730053
  • -36.7% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -47.6% vs -6.3% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -40.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 52 · Phase 3 · secondary NCT01730040
  • -50.5% vs -7.5% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -41.2% vs -18% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -29.8% vs -18% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -40.6% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -42.3% vs -7.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -37.3% vs -4.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · primary NCT02642159
  • -44% vs 2.2% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.4% vs 0.7% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -41.1% vs 1.7% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -40.6% vs 1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -37% vs 2.5% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -35.5% vs -9.4% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -54.5% vs -14.1% wk 36 · n 93 · Phase 4 · secondary NCT02984982
Evolocumab
-41.8% vs 8.4%−50.3 vs placebowk 52 · n 599NCT01516879
50 other results
  • -41.2% vs -6.1% 420 mg QM · wk 24 · n 104 · Phase 3 · secondary NCT02392559
  • -48.1% vs 2.9% wk 24 · n 296 · Phase 3 · secondary NCT02833844
  • -53.4% vs 7.9% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -52.2% vs 7.9% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -54.8% vs 7.9% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -50.0% vs 7.9% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -52.0% vs 7.9% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -51.6% vs 7.9% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -51.0% vs 7.9% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -46.4% vs 7.9% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -59.0% vs 7.9% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -51.0% vs 7.9% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -50.1% vs 1.5% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -49.7% vs 1.5% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -52.9% vs 5.9% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -59.1% vs 4.3% QM · n 332 · Phase 3 · secondary NCT02662569
  • -56.2% vs 5.3% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -49.7% vs 5.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -55.8% vs 5.9% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -46.9% vs -0.6% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -67.8% vs -0.1% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -58.0% vs -0.1% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -68.9% vs -0.1% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -63.3% vs -0.1% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -68.5% vs -1.6% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -61.7% vs -1.6% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -69.7% vs -1.6% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -69.1% vs -1.6% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -53.5% vs 7.0% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -56.1% vs 7.0% QM · n 110 · Phase 3 · secondary NCT01763866
  • -54.4% vs 7.0% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -56.3% vs 7.0% QM · n 110 · Phase 3 · secondary NCT01763866
  • -52.6% vs 7.0% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -55.5% vs 7.0% QM · n 115 · Phase 3 · secondary NCT01763866
  • -52.1% vs 7.0% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -55.7% vs 7.0% QM · n 112 · Phase 3 · secondary NCT01763866
  • -59.3% vs 7.0% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -56.0% vs 7.0% QM · n 115 · Phase 3 · secondary NCT01763866
  • -50.2% vs 1.3% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -52.0% vs 1.3% QM · n 153 · Phase 3 · secondary NCT01763827
  • -55.8% vs 2.7% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -57.3% vs 2.7% QM · n 110 · Phase 3 · secondary NCT01763918
  • -56.6% vs 4.3% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -56.6% vs -0.1% n 280 · Phase 3 · secondary NCT02739984
  • -45.7% vs -14.6% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -48.6% vs -16.5% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -46.1% vs -16.5% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -47.4% vs -14.4% n 145 · Phase 3 · secondary NCT01984424
  • -48.7% vs -17.2% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -49.1% vs -17.2% QM · n 102 · Phase 3 · secondary NCT01763905

ApoB, % change

Alirocumab
-52.8% vs 1.2%−54 vs placebo150 mg Q2W · wk 24 · n 1468NCT01507831
86 other results
  • -54.3% vs 1.2% 150 mg Q2W · wk 24 · n 1444 · Phase 3 · secondary NCT01507831
  • -55.5% vs 0.5% 150 mg Q2W · wk 12 · n 1468 · Phase 3 · secondary NCT01507831
  • -40.2% vs -0.7% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01926782
  • -45.1% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 292 · Phase 3 · secondary NCT01926782
  • -44.8% vs -0.3% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT01926782
  • -47.2% vs 3.1% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 286 · Phase 3 · secondary NCT01926782
  • -46.4% vs -2.3% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 138 · Phase 3 · secondary NCT01926782
  • -41.2% vs 3.6% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 292 · Phase 3 · secondary NCT01926782
  • -41.1% vs 4.7% 75 mg/Up to 150 mg Q2W · wk 24 · n 309 · Phase 3 · secondary NCT01623115
  • -41.4% vs 4.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01623115
  • -34.5% vs 3.1% 75 mg/Up to 150 mg Q2W · wk 12 · n 309 · Phase 3 · secondary NCT01623115
  • -39% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -38.9% vs -8.7% 150 mg Q2W · wk 24 · n 69 · Phase 3 · secondary NCT01617655
  • -36.7% vs -0.9% 75/150 mg Q2W · wk 24 · n 185 · Phase 3 · secondary NCT01644175
  • -37.9% vs -0.4% 75/150 mg Q2W · wk 24 · n 181 · Phase 3 · secondary NCT01644175
  • -39.2% vs -9% 150 mg Q2W · wk 12 · n 69 · Phase 3 · secondary NCT01617655
  • -34.8% vs 3.4% 75/150 mg Q2W · wk 12 · n 185 · Phase 3 · secondary NCT01644175
  • -42.8% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 163 · Phase 3 · secondary NCT01709500
  • -43.2% vs -3.5% 75 mg/up to 150 mg · wk 24 · n 162 · Phase 3 · secondary NCT01709500
  • -33.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 279 · Phase 3 · secondary NCT02585778
  • -38.9% vs 7.5% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -40.9% vs 7.7% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 54 · Phase 3 · secondary NCT02023879
  • -32.2% vs -6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -57.9% vs -6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.8% vs -4.6% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -58% vs -4.6% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -31.3% vs 7% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -39.7% vs 7.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -41.2% vs 7.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 112 · Phase 3 · secondary NCT02023879
  • -39.4% vs 3.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 47 · Phase 3 · secondary NCT02585778
  • -42.3% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 96 · Phase 3 · secondary NCT02289963
  • -45.4% vs 3.8% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 95 · Phase 3 · secondary NCT02289963
  • -55% vs -1.6% 75 mg/Up to 150 mg Q2W · wk 24 · n 141 · Phase 3 · secondary NCT02107898
  • -55.9% vs -2.1% 75 mg/Up to 150 mg Q2W · wk 24 · n 140 · Phase 3 · secondary NCT02107898
  • -38.4% vs 7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 112 · Phase 3 · secondary NCT02023879
  • -40.9% vs 5.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 96 · Phase 3 · secondary NCT02289963
  • -54.6% vs -3.3% 75 mg/Up to 150 mg Q2W · wk 12 · n 141 · Phase 3 · secondary NCT02107898
  • -33.8% vs 1.7% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -22.5% vs 7.2% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -42.8% vs 1.2% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -36.7% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 75 · Phase 3 · secondary NCT01926782
  • -35.4% vs -0.9% 75 mg/up to 150 mg · wk 12 · n 163 · Phase 3 · secondary NCT01709500
  • -39% vs -0.7% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 34 · Phase 3 · secondary NCT01926782
  • -42% vs -0.3% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -38.3% vs 3.1% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 74 · Phase 3 · secondary NCT01926782
  • -40.8% vs -2.3% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 34 · Phase 3 · secondary NCT01926782
  • -33% vs 3.6% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 75 · Phase 3 · secondary NCT01926782
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -27.4% vs -3.6% Q2W · wk 24 · n 47 · Phase 3 · secondary NCT03510884
  • -34.3% vs -3.6% Q4W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -30% vs 1.1% Q2W · wk 12 · n 47 · Phase 3 · secondary NCT03510884
  • -31.7% vs 1.1% Q4W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -40.7% vs -18.3% 75 /up to 150 mg Q2W · wk 24 · n 452 · Phase 3 · secondary NCT01644188
  • -42.1% vs -19.1% 75 /up to 150 mg Q2W · wk 24 · n 442 · Phase 3 · secondary NCT01644188
  • -39.7% vs -17.2% 75 /up to 150 mg Q2W · wk 12 · n 452 · Phase 3 · secondary NCT01644188
  • -43.5% vs -16.2% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 398 · Phase 3 · secondary NCT02715726
  • -45.2% vs -17.4% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 392 · Phase 3 · secondary NCT02715726
  • -43% vs -16.5% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 398 · Phase 3 · secondary NCT02715726
  • -36.7% vs -11% 75/Up to 150 mg Q2W · wk 24 · n 48 · Phase 3 · secondary NCT01644474
  • -37.3% vs -11.7% 75/Up to 150 mg Q2W · wk 12 · n 48 · Phase 3 · secondary NCT01644474
  • -36.3% vs -11.2% 75 mg/ up to 150 mg · wk 24 · n 122 · Phase 3 · secondary NCT01709513
  • -42.6% vs -14.4% 75 mg/ up to 150 mg · wk 24 · n 109 · Phase 3 · secondary NCT01709513
  • -36.1% vs -11.6% 75 mg/ up to 150 mg · wk 12 · n 122 · Phase 3 · secondary NCT01709513
  • -36.5% vs -9.8% 75 mg/up to 150 mg + 10 mg · wk 24 · n 44 · Phase 3 · secondary NCT01730053
  • -28.3% vs -9.8% 75 mg/up to 150 mg + 20 mg · wk 24 · n 49 · Phase 3 · secondary NCT01730053
  • -39.5% vs -12.7% 75 mg/up to 150 mg + 10 mg · wk 24 · n 43 · Phase 3 · secondary NCT01730053
  • -30.4% vs -12.7% 75 mg/up to 150 mg + 20 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -33.7% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730040
  • -41.9% vs -4.4% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 42 · Phase 3 · secondary NCT01730040
  • -37.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 50 · Phase 3 · secondary NCT01730040
  • -42.7% vs -5.1% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 41 · Phase 3 · secondary NCT01730040
  • -36.1% vs -13.7% 75 mg/up to 150 mg + 10 mg · wk 12 · n 44 · Phase 3 · secondary NCT01730053
  • -29% vs -13.7% 75 mg/up to 150 mg + 20 mg · wk 12 · n 49 · Phase 3 · secondary NCT01730053
  • -38.4% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730040
  • -36.2% vs -6.9% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 42 · Phase 3 · secondary NCT01730040
  • -40.9% vs 2.1% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -36.7% vs 0.8% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -39% vs 1.1% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -39.1% vs 0.2% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -36.4% vs 1.4% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -33.8% vs -1.6% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.1% vs -16.6% wk 36 · n 92 · Phase 4 · secondary NCT02984982
Evolocumab
-41.3% vs 2.9%−44.2 vs placebowk 52 · n 599NCT01516879
53 other results
  • -34.9% vs -2.4% 420 mg QM · wk 24 · n 104 · Phase 3 · secondary NCT02392559
  • -45.1% vs 2.6% wk 24 · n 302 · Phase 3 · secondary NCT02833844
  • -48.3% vs 3.3% 420 mg QM · wk 16 · n 63 · Phase 3 · secondary NCT02729025
  • -50.9% vs 6.3% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -47.1% vs 6.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -49.8% vs 6.3% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -46.5% vs 6.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -50.1% vs 6.3% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -48.6% vs 6.3% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -45.6% vs 6.3% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -43.7% vs 6.3% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -56.0% vs 6.3% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -49.2% vs 6.3% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -47.2% vs 1.8% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -46.6% vs 1.8% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -49.7% vs 3.2% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -56.4% vs 2.0% QM · n 332 · Phase 3 · secondary NCT02662569
  • -49.8% vs 4.6% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -44.8% vs 4.6% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -53.9% vs 3.2% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -40.3% vs 1.8% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -64.8% vs -2.5% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -54.8% vs -2.5% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -62.8% vs -2.5% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -64.4% vs -4.3% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -51.0% vs 5.1% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -51.4% vs 5.1% QM · n 110 · Phase 3 · secondary NCT01763866
  • -49.1% vs 5.1% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -53.3% vs 5.1% QM · n 110 · Phase 3 · secondary NCT01763866
  • -49.8% vs 5.1% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -53.6% vs 5.1% QM · n 115 · Phase 3 · secondary NCT01763866
  • -47.1% vs 5.1% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -53.0% vs 5.1% QM · n 112 · Phase 3 · secondary NCT01763866
  • -55.6% vs 5.1% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -54.4% vs 5.1% QM · n 115 · Phase 3 · secondary NCT01763866
  • -47.0% vs 1.5% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -49.4% vs 1.5% QM · n 153 · Phase 3 · secondary NCT01763827
  • -49.6% vs 2.2% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -52.8% vs 2.2% QM · n 110 · Phase 3 · secondary NCT01763918
  • -55.0% vs 2.0% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -50.2% vs 2.3% n 280 · Phase 3 · secondary NCT02739984
  • -19.2% vs 4.0% wk 12 · n 33 · Phase 2/3 · secondary NCT01588496
  • -58.0% vs -2.5% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -64.8% vs -4.3% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -58.5% vs -4.3% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -64.2% vs -4.3% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -20.2% vs 2.6% n 33 · Phase 2/3 · secondary NCT01588496
  • -43.5% vs -11.7% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -45.8% vs -12.9% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -43.1% vs -12.9% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -45.3% vs -11.4% n 145 · Phase 3 · secondary NCT01984424
  • -45.9% vs -13.7% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -46.0% vs -13.7% QM · n 102 · Phase 3 · secondary NCT01763905

Lp(a), % change

Alirocumab
-29.3% vs -3.7%−25.6 vs placebo150 mg Q2W · wk 24 · n 1530NCT01507831
64 other results
  • -28.2% vs -3.1% 150 mg Q2W · wk 12 · n 1530 · Phase 3 · secondary NCT01507831
  • -21.3% vs 6.4% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 · Phase 3 · secondary NCT01926782
  • -19.3% vs 9.8% 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 308 · Phase 3 · secondary NCT01926782
  • -28.9% vs -5.5% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 144 · Phase 3 · secondary NCT01926782
  • -19.6% vs 7% 300 mg Q4W/Up 150 mg Q2W · wk 12 · n 308 · Phase 3 · secondary NCT01926782
  • -23.5% vs -8.7% 150 mg Q2W · wk 24 · n 71 · Phase 3 · secondary NCT01617655
  • -20.5% vs -5.9% 75/150 mg Q2W · wk 24 · n 205 · Phase 3 · secondary NCT01644175
  • -23.2% vs -1.5% 150 mg Q2W · wk 12 · n 71 · Phase 3 · secondary NCT01617655
  • -19.7% vs 0% 75/150 mg Q2W · wk 12 · n 205 · Phase 3 · secondary NCT01644175
  • -25.2% vs -7.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 322 · Phase 3 · secondary NCT01623115
  • -15.5% vs 4.1% 150 mg Q4W/Up to 150 mg Q2W · wk 24 · n 58 · Phase 3 · secondary NCT02023879
  • -31.7% vs 1.3% 150 mg Q4W · wk 12 · n 54 · Phase 3 · secondary NCT02584504
  • -49.6% vs 1.3% 150 mg Q2W · wk 12 · n 53 · Phase 3 · secondary NCT02584504
  • -5.7% vs 2.2% 150 mg Q4W/Up to 150 mg Q2W · wk 12 · n 58 · Phase 3 · secondary NCT02023879
  • -30.3% vs -10% 75 mg/up to 150 mg · wk 24 · n 166 · Phase 3 · secondary NCT01709500
  • -21.8% vs 4.1% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 115 · Phase 3 · secondary NCT02023879
  • -19% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 287 · Phase 3 · secondary NCT02585778
  • -21.2% vs -3.9% 75 mg/Up to 150 mg Q2W · wk 12 · n 322 · Phase 3 · secondary NCT01623115
  • -24.7% vs -5.6% 75 mg/up to 150 mg · wk 12 · n 166 · Phase 3 · secondary NCT01709500
  • -6.1% vs -1.2% 150 mg Q2W · wk 18 · n 41 · Phase 3 · secondary NCT02326220
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -19.6% vs 8.8% 150 mg SC Q2W · wk 12 · n 45 · Phase 3 · secondary NCT03156621
  • -18.1% vs -4% 150 mg Q2W · wk 6 · n 41 · Phase 3 · secondary NCT02326220
  • -14% vs 6.4% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 37 · Phase 3 · secondary NCT01926782
  • -16.9% vs 9.8% 75 mg Q2W/Up 150 mg Q2W · wk 24 · n 76 · Phase 3 · secondary NCT01926782
  • -23% vs -0.5% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 49 · Phase 3 · secondary NCT02585778
  • -35.9% vs -2.3% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 97 · Phase 3 · secondary NCT02289963
  • -39.5% vs 2.5% 75 mg/Up to 150 mg Q2W · wk 24 · n 143 · Phase 3 · secondary NCT02107898
  • -26.9% vs -5.5% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 37 · Phase 3 · secondary NCT01926782
  • -12.4% vs 7% 75 mg Q2W/Up 150 mg Q2W · wk 12 · n 76 · Phase 3 · secondary NCT01926782
  • -16.5% vs 2.2% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 115 · Phase 3 · secondary NCT02023879
  • -33.6% vs -1.7% 75 mg Q2W/Up to 150 mg Q2W · wk 12 · n 97 · Phase 3 · secondary NCT02289963
  • -41.9% vs -0.5% 75 mg/Up to 150 mg Q2W · wk 12 · n 143 · Phase 3 · secondary NCT02107898
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -14.7% vs 2.5% Q2W · wk 24 · n 49 · Phase 3 · secondary NCT03510884
  • -22.4% vs 2.5% Q4W · wk 24 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -12.7% vs -2.5% Q2W · wk 12 · n 49 · Phase 3 · secondary NCT03510884
  • -16.0% vs -2.5% Q4W · wk 12 · n 52 · Phase 3 · secondary NCT03510884
  • -27.8% vs -6.1% 75 /up to 150 mg Q2W · wk 24 · n 467 · Phase 3 · secondary NCT01644188
  • -22.1% vs 1.1% 75 /up to 150 mg Q2W · wk 12 · n 467 · Phase 3 · secondary NCT01644188
  • -30.3% vs 4.0% 75 mg Q2W/up to 150 mg Q2W · wk 24 · n 403 · Phase 3 · secondary NCT02715726
  • -30.1% vs 6.3% 75 mg Q2W/up to 150 mg Q2W · wk 12 · n 403 · Phase 3 · secondary NCT02715726
  • -16.7% vs -12.3% 75/Up to 150 mg Q2W · wk 24 · n 52 · Phase 3 · secondary NCT01644474
  • -17.2% vs -14.2% 75/Up to 150 mg Q2W · wk 12 · n 52 · Phase 3 · secondary NCT01644474
  • -25.9% vs -7.3% 75 mg/ up to 150 mg · wk 24 · n 126 · Phase 3 · secondary NCT01709513
  • -21.7% vs -4.5% 75 mg/ up to 150 mg · wk 12 · n 126 · Phase 3 · secondary NCT01709513
  • -27.9% vs -5.2% 75 mg/up to 150 mg + 10 mg · wk 24 · n 48 · Phase 3 · secondary NCT01730053
  • -22.7% vs -5.2% 75 mg/up to 150 mg + 20 mg · wk 24 · n 53 · Phase 3 · secondary NCT01730053
  • -23.6% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 24 · n 55 · Phase 3 · secondary NCT01730040
  • -30.8% vs -20.2% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 24 · n 46 · Phase 3 · secondary NCT01730040
  • -20.7% vs 3.5% 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 · Phase 3 · secondary NCT01730053
  • -16% vs 3.5% 75 mg/up to 150 mg + 20 mg · wk 12 · n 53 · Phase 3 · secondary NCT01730053
  • -24% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 20 mg · wk 12 · n 55 · Phase 3 · secondary NCT01730040
  • -27.9% vs -11.7% 75 mg/up to 150 mg + Atorvastatin 40 mg · wk 12 · n 46 · Phase 3 · secondary NCT01730040
  • -24.7% vs -0.5% 75 Q2W/Up150 Q2W · wk 24 · n 1058 · Phase 4 · secondary NCT02957682
  • -22.4% vs -3.3% 75 Q2W/Up150 Q2W · wk 12 · n 1058 · Phase 4 · secondary NCT02957682
  • -24.3% vs -1.4% 75 Q2W/Up150 Q2W · wk 48 · n 1058 · Phase 4 · secondary NCT02957682
  • -25.1% vs -1.7% 75 Q2W/Up150 Q2W · wk 72 · n 1058 · Phase 4 · secondary NCT02957682
  • -17.7% vs 4.8% 75 Q2W/Up150 Q2W · wk 96 · n 1058 · Phase 4 · secondary NCT02957682
  • -23.7% vs 3.7% 75 mg Q2W/Up to 150 mg Q2W · wk 24 · n 273 · Phase 4 · secondary NCT02642159
  • -55.8% vs -17.2% wk 36 · n 92 · Phase 4 · secondary NCT02984982
Evolocumab
-16.4% vs 10.3%−26.8 vs placebowk 24 · n 302NCT02833844
52 other results
  • -27.7% vs -5.4% wk 52 · n 599 · Phase 3 · secondary NCT01516879
  • -12.8% vs 1.1% 420 mg QM · wk 16 · n 63 · Phase 3 · secondary NCT02729025
  • -25.9% vs 11.4% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -20.3% vs 11.4% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -24.6% vs 11.4% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -24.7% vs 11.4% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -25.1% vs 11.4% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -20.9% vs 11.4% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -26.1% vs 11.4% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -22.0% vs 11.4% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -38.1% vs 11.4% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -29.2% vs 11.4% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -20.4% vs 0% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -17.8% vs 0% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -25.2% vs 7.4% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -42.3% vs 16.9% QM · n 332 · Phase 3 · secondary NCT02662569
  • -22.9% vs 6.7% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -21.6% vs 6.7% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -35.9% vs 26.5% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -37.9% vs 26.5% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -45.7% vs 10.8% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -41.7% vs 10.8% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -41.9% vs 10.8% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -45.7% vs 10.8% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -45.0% vs 6.5% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -49.5% vs 6.5% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -26.0% vs 11.4% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -22.6% vs 11.4% QM · n 110 · Phase 3 · secondary NCT01763866
  • -24.0% vs 11.4% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -27.5% vs 11.4% QM · n 110 · Phase 3 · secondary NCT01763866
  • -24.3% vs 11.4% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -23.2% vs 11.4% QM · n 115 · Phase 3 · secondary NCT01763866
  • -25.0% vs 11.4% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -25.9% vs 11.4% QM · n 112 · Phase 3 · secondary NCT01763866
  • -38.6% vs 11.4% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -32.2% vs 11.4% QM · n 115 · Phase 3 · secondary NCT01763866
  • -18.4% vs 0% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -19.2% vs 0% QM · n 153 · Phase 3 · secondary NCT01763827
  • -24.0% vs 5.3% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -25.6% vs 5.3% QM · n 110 · Phase 3 · secondary NCT01763918
  • -38.6% vs 16.9% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -30.9% vs 9.6% n 280 · Phase 3 · secondary NCT02739984
  • -9.4% vs 2.4% wk 12 · n 33 · Phase 2/3 · secondary NCT01588496
  • -46.0% vs 6.5% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -43.0% vs 6.5% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -12.7% vs -1.4% n 33 · Phase 2/3 · secondary NCT01588496
  • -21.1% vs 0.2% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -27.0% vs -1.7% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -22.1% vs -1.7% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -22.7% vs -1.6% n 145 · Phase 3 · secondary NCT01984424
  • -26.2% vs -2.3% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -23.7% vs -2.3% QM · n 102 · Phase 3 · secondary NCT01763905

3-point MACE (% with event)

Alirocumab
—Not posted · NCT04790513
Evolocumab
7.9% vs 9.9%−2 vs placebowk 156 · n 13784NCT01764633
5 other results
  • 6.7% vs 8.3% wk 130 · n 13784 · Phase 3 · secondary NCT01764633
  • 5.5% vs 6.8% wk 104 · n 13784 · Phase 3 · secondary NCT01764633
  • 4.3% vs 5.2% wk 78 · n 13784 · Phase 3 · secondary NCT01764633
  • 3.1% vs 3.7% wk 52 · n 13784 · Phase 3 · secondary NCT01764633
  • 1.6% vs 1.9% wk 26 · n 13784 · Phase 3 · secondary NCT01764633
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
20 other shared endpoints and safety

Coverage. Alirocumab: 24 of 24 rows · Evolocumab: 24 of 24 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlirocumab
Rows use multiple source trials
Evolocumab
Rows use multiple source trials
All-cause Mortality
responder rate · % of participants
3.5% (n=9462) vs 4.1% (n=9462) placebo75 mg Q2W/Up to 150 mg Q2Wa,b,c
NCT01663402 · Phase 3
4.75% (n=13784) vs 4.28% (n=13780) placebo @ 156wka,b,c
NCT01764633 · Phase 3
Apo B
percent change · % of baseline
No placebo or comparator arm
-43.1% (n=651) @ 168wk75 or 150 mg Q2Wd,a,b
NCT01954394 · Phase 3 · registry result, not featured evidence
-20.38% (n=106) @ 168wkd,a,b
NCT01624142 · Phase 2/3
CANTAB SWM Strategy
absolute change · score
-1 vs -0.9 placebo score @ 96wk75 Q2W/Up150 Q2We,a,b,c
NCT02957682 · Phase 4 · registry result, not featured evidence
0.1134 vs 0.1206 placebo scoree,a,b,c
NCT02207634 · Phase 3
Coronary Revascularization
responder rate · % of participants
7.7% (n=9462) vs 8.8% (n=9462) placebo75 mg Q2W/Up to 150 mg Q2Wa,b,c
NCT01663402 · Phase 3
7.01% (n=13784) vs 9.17% (n=13780) placebo @ 156wka,b,c
NCT01764633 · Phase 3
CV Death
responder rate · % of participants
2.5% (n=9462) vs 2.9% (n=9462) placebo75 mg Q2W/Up to 150 mg Q2Wa,b,c
NCT01663402 · Phase 3
2.49% (n=13784) vs 2.39% (n=13780) placebo @ 156wka,b,c
NCT01764633 · Phase 3
HDL-C
percent change · % of baseline
4% (n=1530) vs -0.6% (n=780) placebo @ 24wk150 mg Q2Wa,b,c
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
27 other source trials
3.5% (n=205) vs -3.8% (n=106) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
8.8% (n=322) vs 0.8% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
6% (n=166) vs -0.8% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
3.6% (n=308) vs -1.5% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
2.5% (n=144) vs -5.3% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
6% (n=76) vs -1.5% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-0.1% (n=37) vs -5.3% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
8.6% (n=467) vs 0.5% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
6% (n=52) vs 1.6% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
5.6% (n=49) vs -0.8% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
5.6% (n=49) vs -0.8% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
3.4% (n=50) vs -0.8% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
3.4% (n=50) vs -0.8% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
9% (n=1058) vs 3.8% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
14.5% (n=273) vs 8.2% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
8.3% (n=403) vs 6.5% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
7.7% (n=58) vs -2.4% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
7.4% (n=115) vs -2.4% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
7.7% (n=126) vs 6.8% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
11.2% (n=49) vs 7.3% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
8.1% (n=287) vs 7.3% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
13.8% (n=97) vs 6.2% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
7.9% (n=143) vs 2.1% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
9.1% (n=48) vs 1.7% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
7.2% (n=53) vs 1.7% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
4.8% (n=55) vs 1.9% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
7.7% (n=46) vs 1.9% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
5.54% (n=110) vs -0.99% (n=56) placeboQ2Wf,a,b,c
NCT01763866 · Phase 3
show 9 more doses
7.66% (n=110) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
8.44% (n=109) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
7.76% (n=110) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
4.86% (n=111) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
6.35% (n=112) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
6.23% (n=113) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
7.72% (n=115) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
10.35% (n=112) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
6.71% (n=115) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
LDL-C
absolute change · mg/dL
-62.4 vs -9.6 Standard of Care mg/dL @ 12wke,a,b
NCT02984982 · Phase 4 · registry result, not featured evidence
-76.8 vs 6.8 placebo mg/dLQ2Wf,e,a,b
NCT01763866 · Phase 3
show 19 more doses
-77 vs 8.6 placebo mg/dL @ 12wkQ2W
NCT01763866 · Phase 3
-80.1 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-75.1 vs 8.6 placebo mg/dL @ 12wkQM
NCT01763866 · Phase 3
-58.8 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-59 vs 8.6 placebo mg/dL @ 12wkQ2W
NCT01763866 · Phase 3
-60.1 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-54.8 vs 8.6 placebo mg/dL @ 12wkQM
NCT01763866 · Phase 3
-52.3 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-52.1 vs 8.6 placebo mg/dL @ 12wkQ2W
NCT01763866 · Phase 3
-55.3 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-46.7 vs 8.6 placebo mg/dL @ 12wkQM
NCT01763866 · Phase 3
-68.9 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-69.2 vs 8.6 placebo mg/dL @ 12wkQ2W
NCT01763866 · Phase 3
-77.8 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-73.3 vs 8.6 placebo mg/dL @ 12wkQM
NCT01763866 · Phase 3
-83.8 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-83.5 vs 8.6 placebo mg/dL @ 12wkQ2W
NCT01763866 · Phase 3
-78.4 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-72.5 vs 8.6 placebo mg/dL @ 12wkQM
NCT01763866 · Phase 3
LDL-C
percent change · % of baseline
No placebo or comparator arm
-52.2% (n=651) @ 168wk75 or 150 mg Q2Wd,a,b
NCT01954394 · Phase 3 · registry result, not featured evidence
-29.52% (n=106) @ 168wkd,a,b
NCT01624142 · Phase 2/3
2 other source trials
-64.5% (n=82)
NCT01879319 · Phase 3 · registry result, not featured evidence
-67.9% (n=82)
NCT01879319 · Phase 3 · registry result, not featured evidence
LDL-C
absolute change · mg/dL
No placebo or comparator arm
-99.4 mg/dL @ 168wk75 or 150 mg Q2Wa,b,g
NCT01954394 · Phase 3 · registry result, not featured evidence
-63.1 mg/dL @ 80wk420 mg QMf,a,b,g
NCT02624869 · Phase 3
show 2 more doses
-67.2 mg/dL @ 80wk420 mg QM
NCT02624869 · Phase 3
-36.5 mg/dL @ 80wk420 mg QM
NCT02624869 · Phase 3
LDL-C
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
-55.67% (n=42) @ 52wkh,a,b
NCT01576484 · Phase 2 · registry result, not featured evidence
-51.3% (n=770) @ 52wkh,a,b
NCT02304484 · Phase 3 · registry result, not featured evidence
LDL-C 15% Reduction
responder rate · % of participants
No placebo or comparator arm
39% (n=18) @ 48wkd,i,b
NCT03510715 · Phase 3 · registry result, not featured evidence
60.2% (n=106) @ 48wkd,i,b
NCT01624142 · Phase 2/3
LDL-C 50 Reduction
responder rate · % of participants
43.9% (n=41) vs 0% (n=21) placebo @ 18wk150 mg Q2Wi,b,j
NCT02326220 · Phase 3
72.5% (n=295) vs 0.7% (n=151) placebo @ 24wki,b,j
NCT02833844 · Phase 3 · registry result, not featured evidence
1 other source trial
84.2% (n=280) vs 0.7% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
LDL-C Less Than 70
responder rate · % of participants
79.3% (n=1530) vs 8% (n=780) placebo @ 24wk150 mg Q2Wf,a,b,c
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more dose
81.2% (n=1523) vs 8% (n=777) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
88.1% (n=110) vs 5.7% (n=56) placeboQ2Wf,a,b,c
NCT01763866 · Phase 3
show 9 more doses
85.8% (n=110) vs 5.7% (n=56) placeboQM
NCT01763866 · Phase 3
94.4% (n=109) vs 5.7% (n=56) placeboQ2W
NCT01763866 · Phase 3
92.5% (n=110) vs 5.7% (n=56) placeboQM
NCT01763866 · Phase 3
93.5% (n=111) vs 5.7% (n=56) placeboQ2W
NCT01763866 · Phase 3
94.5% (n=112) vs 5.7% (n=56) placeboQM
NCT01763866 · Phase 3
88.7% (n=113) vs 5.7% (n=56) placeboQ2W
NCT01763866 · Phase 3
89.9% (n=115) vs 5.7% (n=56) placeboQM
NCT01763866 · Phase 3
93.6% (n=112) vs 5.7% (n=56) placeboQ2W
NCT01763866 · Phase 3
88.5% (n=115) vs 5.7% (n=56) placeboQM
NCT01763866 · Phase 3
Lp(a
percent change · % of baseline
No placebo or comparator arm
-29.2% (n=651) @ 168wk75 or 150 mg Q2Wd,a,b
NCT01954394 · Phase 3 · registry result, not featured evidence
-22.94% (n=106) @ 168wkd,a,b
NCT01624142 · Phase 2/3
MACE Composite
responder rate · % of participants
9.5% (n=9462) vs 11.1% (n=9462) placebo75 mg Q2W/Up to 150 mg Q2Wa,b,c
NCT01663402 · Phase 3
12.57% (n=13784) vs 14.64% (n=13780) placebo @ 156wka,b,c
NCT01764633 · Phase 3
Non-HDL-C
percent change · % of baseline
No placebo or comparator arm
-47.7% (n=651) @ 168wk75 or 150 mg Q2Wd,a,b
NCT01954394 · Phase 3 · registry result, not featured evidence
-27.97% (n=106) @ 168wkd,a,b
NCT01624142 · Phase 2/3
PAV
absolute change · percentage points
-1.42% (n=93) vs -1.28% (n=89) Standard of Care @ 36wke,a,b,k
NCT02984982 · Phase 4 · registry result, not featured evidence
-0.955% (n=423) vs 0.053% (n=423) placebo @ 78wke,a,b,k
NCT01813422 · Phase 3 · registry result, not featured evidence
Stroke
responder rate · % of participants
1.2% (n=9462) vs 1.6% (n=9462) placebo75 mg Q2W/Up to 150 mg Q2Wa,b,c
NCT01663402 · Phase 3
2.18% (n=13784) vs 2.6% (n=13780) placebo @ 156wkf,a,b,c
NCT01764633 · Phase 3
show 1 more dose
2.48% (n=13784) vs 2.81% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
Total Cholesterol
percent change · % of baseline
-27.9% (n=205) vs -2.9% (n=106) placebo @ 24wk75/150 mg Q2Wi,b
NCT01644175 · Phase 3
10 other source trials
-29.6% (n=52) vs -10.9% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-23.4% (n=49) vs 7.4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-23.4% (n=49) vs 7.4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-27.7% (n=50) vs 7.4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-27.7% (n=50) vs 7.4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-27.4% (n=273) vs -2.8% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
-33.9% (n=403) vs -13.8% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-29.9% (n=49) vs -0.7% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-26.8% (n=287) vs -0.7% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-31.2% (n=97) vs 4% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-35.78% (n=296) vs 2.34% (n=152) placebo @ 24wki,b
NCT02833844 · Phase 3 · registry result, not featured evidence
5 other source trials
-38.64% (n=325) vs 2.89% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-39.74% (n=332) vs 2.89% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-38.04% (n=145) vs -11.43% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-36.64% (n=145) vs -11.57% (n=73) Ezetimibe @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
-42.19% (n=280) vs -1.13% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
Triglycerides
percent change · % of baseline
-2.4% (n=41) vs 4.1% (n=21) placebo @ 18wk150 mg Q2Wa,b,l
NCT02326220 · Phase 3
-2.55% (n=599) vs 8.99% (n=302) placebo @ 52wka,b,l
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
20 other source trials
-5.61% (n=110) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-13.38% (n=110) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-9.27% (n=109) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-6.36% (n=110) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-9.15% (n=111) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-15.43% (n=112) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-10.28% (n=113) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-7.26% (n=115) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-11.67% (n=112) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-15.93% (n=115) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-9.16% (n=153) vs -3.89% (n=76) placeboQ2W
NCT01763827 · Phase 3
-15.71% (n=153) vs -3.89% (n=76) placeboQM
NCT01763827 · Phase 3
-13.27% (n=110) vs 9.09% (n=54) placeboQ2W
NCT01763918 · Phase 3
-9.25% (n=110) vs 9.09% (n=54) placeboQM
NCT01763918 · Phase 3
-6.48% (n=325) vs 11.54% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-7.15% (n=332) vs 11.54% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-5.39% (n=145) vs -0.95% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-12.64% (n=280) vs 6.61% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
-6.32% (n=103) vs -3.74% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-6.73% (n=102) vs -3.74% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
Dropout rate
28.3%150 mg Q2Wm
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 84 more results
40.3%150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—150 Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—75 /up to 150 mg Q2W
NCT01644175 · Phase 3
25.4%75/150 mg Q2W
NCT01644175 · Phase 3
—75/Up to 150 mg Q2W
NCT01623115 · Phase 3
23.8%75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
n/a: no completion milestone75 mg/up to 150 mg
NCT01709500 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
12.8%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
28.1%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
16.7%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
21.6%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
9.8%150 mg Q2W
NCT02326220 · Phase 3
25.5%75 /up to 150 mg Q2W
NCT01644188 · Phase 3
—75/Up to 150 mg Q2W
NCT01644188 · Phase 3
15.4%75/Up to 150 mg Q2W
NCT01644474 · Phase 3
—75/Up150 mg Q2W
NCT01644474 · Phase 3
0%150 mg SC Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
8.2%Q2W
NCT03510884 · Phase 3
5.8%Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
0%Q2W
NCT03510884 · Phase 3
3.7%Q4W
NCT03510884 · Phase 3
22%75 mg Q2W/Up to 150 mg Q2W
NCT01663402 · Phase 3
—Alirocumab
NCT01663402 · Phase 3
15.5%75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
0%
NCT02938949 · Phase 4 · registry result, not featured evidence
9.6%
NCT02984982 · Phase 4 · registry result, not featured evidence
11.2%75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
12%
NCT02476006 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Parallel
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Single-a
NCT03415178 · Phase 3 · registry result, not featured evidence
5.7%New Auto-injector Device (SYDNEY)
NCT03415178 · Phase 3 · registry result, not featured evidence
6.6%75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/up150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
3.8%150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
0%150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
8.7%75 or 150 mg Q2W
NCT01954394 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
15.3%150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
23.8%75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
9.6%75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
10.3%75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
—75 mg/ Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
8.3%75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
22.4%75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
24.1%75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
19.3%75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
19.1%75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
0%300 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm/ApoB LOFm: Alirocumab F
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm: Alirocumab From Day 1
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm: Alirocumab From Day 15
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
41.3%
NCT01576484 · Phase 2 · registry result, not featured evidence
5.6%n
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 64 more results
0%Part A: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0.7%
NCT01764633 · Phase 3
3.2%
NCT02207634 · Phase 3
1.8%Q2W
NCT01763866 · Phase 3
2.7%QM
NCT01763866 · Phase 3
7.3%Q2W
NCT01763866 · Phase 3
1.8%QM
NCT01763866 · Phase 3
5.4%Q2W
NCT01763866 · Phase 3
1.8%QM
NCT01763866 · Phase 3
10.5%Q2W
NCT01763866 · Phase 3
2.6%QM
NCT01763866 · Phase 3
2.7%Q2W
NCT01763866 · Phase 3
1.7%QM
NCT01763866 · Phase 3
3.9%Q2W
NCT01763827 · Phase 3
1.3%QM
NCT01763827 · Phase 3
9%Q2W
NCT01763918 · Phase 3
1.8%QM
NCT01763918 · Phase 3
1%420 mg QM
NCT02392559 · Phase 3
—420 mg QM
NCT02392559 · Phase 3
30.2%
NCT01624142 · Phase 2/3
3%420 mg QM
NCT02624869 · Phase 3
2%420 mg QM
NCT02624869 · Phase 3
15.4%420 mg QM
NCT02624869 · Phase 3
38.3%
NCT04608474 · Phase 4 · registry result, not featured evidence
0%HPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
0%NPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
3.3%
NCT03403374 · Phase 4 · registry result, not featured evidence
14.5%
NCT03689946 · Phase 3 · registry result, not featured evidence
16.4%Once Every 2 Weeks (Q2W) or Once a Month (QM)
NCT02867813 · Phase 3 · registry result, not featured evidence
—Evolocumab in Parent Study
NCT02867813 · Phase 3 · registry result, not featured evidence
3.7%
NCT03570697 · Phase 3 · registry result, not featured evidence
—
NCT02833844 · Phase 3 · registry result, not featured evidence
2.6%Evolocumab + Standard of Care
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Year 1: Evolocumab + Standard of C
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Years 2-3: Evolocumab + SOC / Evol
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Years 2-3: SOC / Evolocumab + SOC
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Q2W
NCT02634580 · Phase 3 · registry result, not featured evidence
—QM
NCT02634580 · Phase 3 · registry result, not featured evidence
1.5%420 mg QM
NCT02729025 · Phase 3 · registry result, not featured evidence
3.2%
NCT02304484 · Phase 3 · registry result, not featured evidence
1.8%Q2W
NCT02662569 · Phase 3 · registry result, not featured evidence
1.2%QM
NCT02662569 · Phase 3 · registry result, not featured evidence
4.8%
NCT01984424 · Phase 3 · registry result, not featured evidence
0.7%
NCT02739984 · Phase 3 · registry result, not featured evidence
3.3%
NCT01813422 · Phase 3 · registry result, not featured evidence
13%Evolocumab
NCT02189837 · Phase 3 · registry result, not featured evidence
9.5%Evolocumab and Atorvastatin
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
0%Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
0%QM
NCT01953328 · Phase 3 · registry result, not featured evidence
0%Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
0%QM
NCT01953328 · Phase 3 · registry result, not featured evidence
8.7%Q2W
NCT01763905 · Phase 3 · registry result, not featured evidence
1%QM
NCT01763905 · Phase 3 · registry result, not featured evidence
6.1%Evolocumab AI/Pen
NCT01879319 · Phase 3 · registry result, not featured evidence
2.4%Evolocumab AMD
NCT01879319 · Phase 3 · registry result, not featured evidence
5.4%Evolocumab AI/Pen
NCT01849497 · Phase 3 · registry result, not featured evidence
1.3%Evolocumab PFS
NCT01849497 · Phase 3 · registry result, not featured evidence
—All-IP Period: Evolocumab + SOC /
NCT01439880 · Phase 2 · registry result, not featured evidence
—All-IP Period: SOC / Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence
6.8%Evolocumab + SOC
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
—SOC-controlled Period: Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
7.3%150 mg Q2Wm
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 84 more results
4.2%150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—150 Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—75 /up to 150 mg Q2W
NCT01644175 · Phase 3
6.2%75/150 mg Q2W
NCT01644175 · Phase 3
—75/Up to 150 mg Q2W
NCT01623115 · Phase 3
4%75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
3%75 mg/up to 150 mg
NCT01709500 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
5.4%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
9.6%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
5.1%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
8.1%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
4.9%150 mg Q2W
NCT02326220 · Phase 3
9.2%75 /up to 150 mg Q2W
NCT01644188 · Phase 3
—75/Up to 150 mg Q2W
NCT01644188 · Phase 3
9.6%75/Up to 150 mg Q2W
NCT01644474 · Phase 3
—75/Up150 mg Q2W
NCT01644474 · Phase 3
—150 mg SC Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
0%Q2W
NCT03510884 · Phase 3
3.8%Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
0%Q2W
NCT03510884 · Phase 3
0%Q4W
NCT03510884 · Phase 3
3.8%75 mg Q2W/Up to 150 mg Q2W
NCT01663402 · Phase 3
—Alirocumab
NCT01663402 · Phase 3
6.2%75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
—
NCT02938949 · Phase 4 · registry result, not featured evidence
4.8%
NCT02984982 · Phase 4 · registry result, not featured evidence
3.6%75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
4.1%
NCT02476006 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Parallel
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-Injector Device (Single-a
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-injector Device (SYDNEY)
NCT03415178 · Phase 3 · registry result, not featured evidence
1.5%75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/up150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
1.9%150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
0%150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
3.5%75 or 150 mg Q2W
NCT01954394 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
8.5%150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
18.3%75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
4.9%75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
2.1%75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
—75 mg/ Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
4.9%75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
6.1%75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
3.7%75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
8.8%75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
4.3%75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
—300 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
—50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
—PCSK9 GOFm/ApoB LOFm: Alirocumab F
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9 GOFm: Alirocumab From Day 1
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9 GOFm: Alirocumab From Day 15
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
2.2%
NCT01576484 · Phase 2 · registry result, not featured evidence
—n
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 64 more results
—Part A: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—
NCT01764633 · Phase 3
—
NCT02207634 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763827 · Phase 3
—QM
NCT01763827 · Phase 3
—Q2W
NCT01763918 · Phase 3
—QM
NCT01763918 · Phase 3
—420 mg QM
NCT02392559 · Phase 3
—420 mg QM
NCT02392559 · Phase 3
—
NCT01624142 · Phase 2/3
—420 mg QM
NCT02624869 · Phase 3
—420 mg QM
NCT02624869 · Phase 3
—420 mg QM
NCT02624869 · Phase 3
6.2%
NCT04608474 · Phase 4 · registry result, not featured evidence
—HPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
—NPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
—
NCT03403374 · Phase 4 · registry result, not featured evidence
—
NCT03689946 · Phase 3 · registry result, not featured evidence
—Once Every 2 Weeks (Q2W) or Once a Month (QM)
NCT02867813 · Phase 3 · registry result, not featured evidence
—Evolocumab in Parent Study
NCT02867813 · Phase 3 · registry result, not featured evidence
—
NCT03570697 · Phase 3 · registry result, not featured evidence
—
NCT02833844 · Phase 3 · registry result, not featured evidence
—Evolocumab + Standard of Care
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Year 1: Evolocumab + Standard of C
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Years 2-3: Evolocumab + SOC / Evol
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Years 2-3: SOC / Evolocumab + SOC
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Q2W
NCT02634580 · Phase 3 · registry result, not featured evidence
—QM
NCT02634580 · Phase 3 · registry result, not featured evidence
—420 mg QM
NCT02729025 · Phase 3 · registry result, not featured evidence
—
NCT02304484 · Phase 3 · registry result, not featured evidence
—Q2W
NCT02662569 · Phase 3 · registry result, not featured evidence
—QM
NCT02662569 · Phase 3 · registry result, not featured evidence
—
NCT01984424 · Phase 3 · registry result, not featured evidence
—
NCT02739984 · Phase 3 · registry result, not featured evidence
—
NCT01813422 · Phase 3 · registry result, not featured evidence
—Evolocumab
NCT02189837 · Phase 3 · registry result, not featured evidence
—Evolocumab and Atorvastatin
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
—Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
—QM
NCT01953328 · Phase 3 · registry result, not featured evidence
—Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
—QM
NCT01953328 · Phase 3 · registry result, not featured evidence
—Q2W
NCT01763905 · Phase 3 · registry result, not featured evidence
—QM
NCT01763905 · Phase 3 · registry result, not featured evidence
—Evolocumab AI/Pen
NCT01879319 · Phase 3 · registry result, not featured evidence
—Evolocumab AMD
NCT01879319 · Phase 3 · registry result, not featured evidence
—Evolocumab AI/Pen
NCT01849497 · Phase 3 · registry result, not featured evidence
—Evolocumab PFS
NCT01849497 · Phase 3 · registry result, not featured evidence
—All-IP Period: Evolocumab + SOC /
NCT01439880 · Phase 2 · registry result, not featured evidence
—All-IP Period: SOC / Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence
—Evolocumab + SOC
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
—SOC-controlled Period: Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
18.7%150 mg Q2Wm
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 84 more results
—150 mg Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
13.9%150 Q2W
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
12.6%75 /up to 150 mg Q2W
NCT01644175 · Phase 3
—75/150 mg Q2W
NCT01644175 · Phase 3
13.7%75/Up to 150 mg Q2W
NCT01623115 · Phase 3
—75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
6%75 mg/up to 150 mg
NCT01709500 · Phase 3
11.6%300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
—300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
11.3%75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
—75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
9.8%150 mg Q2W
NCT02326220 · Phase 3
3.4%150 mg Q2W
NCT02326220 · Phase 3
—150 mg Q2W
NCT02326220 · Phase 3
—75 /up to 150 mg Q2W
NCT01644188 · Phase 3
25.9%75/Up to 150 mg Q2W
NCT01644188 · Phase 3
—75/Up to 150 mg Q2W
NCT01644474 · Phase 3
1.9%75/Up150 mg Q2W
NCT01644474 · Phase 3
—150 mg SC Q2W
NCT03156621 · Phase 3
0%150 Q2W
NCT03156621 · Phase 3
2.2%150 Q2W
NCT03156621 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
8.2%Q2W
NCT03510884 · Phase 3
3.8%Q4W
NCT03510884 · Phase 3
8.7%Q2W
NCT03510884 · Phase 3
6.1%Q4W
NCT03510884 · Phase 3
0%Q2W
NCT03510884 · Phase 3
8%Q4W
NCT03510884 · Phase 3
—Q2W
NCT03510884 · Phase 3
—Q4W
NCT03510884 · Phase 3
—75 mg Q2W/Up to 150 mg Q2W
NCT01663402 · Phase 3
23.3%Alirocumab
NCT01663402 · Phase 3
17.4%75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
40%
NCT02938949 · Phase 4 · registry result, not featured evidence
18.4%
NCT02984982 · Phase 4 · registry result, not featured evidence
9.5%75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
16.2%
NCT02476006 · Phase 3 · registry result, not featured evidence
3%New Auto-Injector Device (Parallel
NCT03415178 · Phase 3 · registry result, not featured evidence
3%New Auto-Injector Device (Single-a
NCT03415178 · Phase 3 · registry result, not featured evidence
—New Auto-injector Device (SYDNEY)
NCT03415178 · Phase 3 · registry result, not featured evidence
—75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
10.1%75 mg Q2W/up150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
—150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
—150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
3.8%150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
1.9%150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
7.6%150 mg Q4W/Up Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
22%75 or 150 mg Q2W
NCT01954394 · Phase 3 · registry result, not featured evidence
29.2%150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
26.4%150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
29.4%150 mg Q4W
NCT02023879 · Phase 3 · registry result, not featured evidence
—150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
12.1%150 mg Q4W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
6.1%75 mg Q2W/Up150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
9.5%75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
9%75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
17.5%75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
7%75 mg/ Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
—75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
4.1%75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
7.4%75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
5.3%75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
2.1%75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
0%300 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%150 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%75 mg Q4W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%50 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%40 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%30 mg Q2W
NCT02890992 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm/ApoB LOFm: Alirocumab F
NCT01604824 · Phase 2 · registry result, not featured evidence
16.7%PCSK9 GOFm: Alirocumab From Day 1
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9 GOFm: Alirocumab From Day 15
NCT01604824 · Phase 2 · registry result, not featured evidence
—PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr
NCT01604824 · Phase 2 · registry result, not featured evidence
17.4%
NCT01576484 · Phase 2 · registry result, not featured evidence
5.5%n
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 64 more results
—Part A: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
24.8%
NCT01764633 · Phase 3
21.6%
NCT02207634 · Phase 3
3.6%Q2W
NCT01763866 · Phase 3
1.8%QM
NCT01763866 · Phase 3
2.8%Q2W
NCT01763866 · Phase 3
0.9%QM
NCT01763866 · Phase 3
0.9%Q2W
NCT01763866 · Phase 3
2.7%QM
NCT01763866 · Phase 3
2.7%Q2W
NCT01763866 · Phase 3
2.6%QM
NCT01763866 · Phase 3
1.8%Q2W
NCT01763866 · Phase 3
0.9%QM
NCT01763866 · Phase 3
2%Q2W
NCT01763827 · Phase 3
0.7%QM
NCT01763827 · Phase 3
2.7%Q2W
NCT01763918 · Phase 3
3.6%QM
NCT01763918 · Phase 3
—420 mg QM
NCT02392559 · Phase 3
1%420 mg QM
NCT02392559 · Phase 3
27.4%
NCT01624142 · Phase 2/3
2%420 mg QM
NCT02624869 · Phase 3
4.1%420 mg QM
NCT02624869 · Phase 3
16.7%420 mg QM
NCT02624869 · Phase 3
0%
NCT04608474 · Phase 4 · registry result, not featured evidence
5.3%HPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
4.5%NPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
6.7%
NCT03403374 · Phase 4 · registry result, not featured evidence
0%
NCT03689946 · Phase 3 · registry result, not featured evidence
—Once Every 2 Weeks (Q2W) or Once a Month (QM)
NCT02867813 · Phase 3 · registry result, not featured evidence
41.8%Evolocumab in Parent Study
NCT02867813 · Phase 3 · registry result, not featured evidence
16.3%
NCT03570697 · Phase 3 · registry result, not featured evidence
3.3%
NCT02833844 · Phase 3 · registry result, not featured evidence
—Evolocumab + Standard of Care
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
7.9%Year 1: Evolocumab + Standard of C
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
14.4%Years 2-3: Evolocumab + SOC / Evol
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
15.1%Years 2-3: SOC / Evolocumab + SOC
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
0%Q2W
NCT02634580 · Phase 3 · registry result, not featured evidence
0%QM
NCT02634580 · Phase 3 · registry result, not featured evidence
3.1%420 mg QM
NCT02729025 · Phase 3 · registry result, not featured evidence
19.9%
NCT02304484 · Phase 3 · registry result, not featured evidence
3.1%Q2W
NCT02662569 · Phase 3 · registry result, not featured evidence
6.6%QM
NCT02662569 · Phase 3 · registry result, not featured evidence
6.2%
NCT01984424 · Phase 3 · registry result, not featured evidence
5%
NCT02739984 · Phase 3 · registry result, not featured evidence
27.9%
NCT01813422 · Phase 3 · registry result, not featured evidence
0%Evolocumab
NCT02189837 · Phase 3 · registry result, not featured evidence
5%Evolocumab and Atorvastatin
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
0%Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
0%QM
NCT01953328 · Phase 3 · registry result, not featured evidence
0%Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
2%QM
NCT01953328 · Phase 3 · registry result, not featured evidence
4.9%Q2W
NCT01763905 · Phase 3 · registry result, not featured evidence
1%QM
NCT01763905 · Phase 3 · registry result, not featured evidence
1.2%Evolocumab AI/Pen
NCT01879319 · Phase 3 · registry result, not featured evidence
0%Evolocumab AMD
NCT01879319 · Phase 3 · registry result, not featured evidence
2.7%Evolocumab AI/Pen
NCT01849497 · Phase 3 · registry result, not featured evidence
4%Evolocumab PFS
NCT01849497 · Phase 3 · registry result, not featured evidence
22%All-IP Period: Evolocumab + SOC /
NCT01439880 · Phase 2 · registry result, not featured evidence
19.6%All-IP Period: SOC / Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence
—Evolocumab + SOC
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
8.2%SOC-controlled Period: Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
150 mg Q2Wm
nasopharyngitis 13.5% (placebo 13.1%)
upper respiratory tract infection 7.4% (placebo 8.6%)
injection site reaction 5.9% (placebo 4.2%)
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 60 more results
150 Q2W
nasopharyngitis 13.9% (placebo 11.4%)
influenza 12.5% (placebo 2.9%)
injection site reaction 8.3% (placebo 5.7%)
NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
75 /up to 150 mg Q2W
upper respiratory tract infection 7.7% (placebo 10.3%)
nasopharyngitis 7.2% (placebo 4.7%)
urinary tract infection 6.3% (placebo 3.7%)
NCT01644175 · Phase 3
75/Up to 150 mg Q2W
injection site reaction 12.4% (placebo 11%)
nasopharyngitis 11.2% (placebo 7.4%)
upper respiratory tract infection 6.8% (placebo 8.6%)
NCT01623115 · Phase 3
75 mg/up to 150 mg
influenza 14.4% (placebo 7.4%)
injection site reaction 10.8% (placebo 7.4%)
nasopharyngitis 10.8% (placebo 19.8%)
NCT01709500 · Phase 3
300 mg Q4W/Up 150 mg Q2W
injection site reaction 16.2% (placebo 7%)
upper respiratory tract infection 9% (placebo 7.9%)
nasopharyngitis 8.5% (placebo 7.9%)
NCT01926782 · Phase 3
75 mg Q2W/Up 150 mg Q2W
injection site reaction 8.7% (placebo 7%)
nasopharyngitis 8.7% (placebo 7.9%)
upper respiratory tract infection 7% (placebo 7.9%)
NCT01926782 · Phase 3
150 mg Q2W
fatigue 14.6% (placebo 9.5%)
myalgia 12.2% (placebo 4.8%)
diarrhoea 9.8% (placebo 0%)
NCT02326220 · Phase 3
150 mg Q2W
anaemia 6.9% (placebo 0%)
nasopharyngitis 3.4% (placebo 9.5%)
arthralgia 0% (placebo 9.5%)
NCT02326220 · Phase 3
75/Up to 150 mg Q2W
accidental overdose 9.8%
upper respiratory tract infection 8.8%
hypertension 6.5%
NCT01644188 · Phase 3
75/Up150 mg Q2W
nasopharyngitis 23.1%
diarrhoea 11.5%
influenza 11.5%
NCT01644474 · Phase 3
150 Q2W
diarrhoea 6.7% (placebo 0%)
headache 4.4% (placebo 8.3%)
nasopharyngitis 4.4% (placebo 0%)
NCT03156621 · Phase 3
150 Q2W
nasopharyngitis 6.7% (placebo 0%)
diarrhoea 2.2% (placebo 0%)
headache 2.2% (placebo 8.3%)
NCT03156621 · Phase 3
Q2W
nasopharyngitis 14.3% (placebo 8%)
headache 6.1% (placebo 8%)
injection site reaction 6.1% (placebo 0%)
NCT03510884 · Phase 3
Q4W
headache 7.7% (placebo 8%)
upper respiratory tract infection 5.8% (placebo 12%)
injection site reaction 3.8% (placebo 0%)
NCT03510884 · Phase 3
Q2W
headache 10.9% (placebo 8%)
oropharyngeal pain 8.7% (placebo 0%)
injection site reaction 6.5% (placebo 0%)
NCT03510884 · Phase 3
Q4W
headache 14.3% (placebo 8%)
covid-19 8.2% (placebo 0%)
nasopharyngitis 6.1% (placebo 8%)
NCT03510884 · Phase 3
Q2W
low density lipoprotein decreased 8% (placebo 0%)
nasopharyngitis 8% (placebo 8%)
nausea 8% (placebo 0%)
NCT03510884 · Phase 3
Q4W
headache 16% (placebo 8%)
covid-19 4% (placebo 0%)
injection site reaction 4% (placebo 0%)
NCT03510884 · Phase 3
nasopharyngitis 6% (placebo 5.6%)
hypertension 5.7% (placebo 6.1%)
myalgia 5.5% (placebo 5.3%)
NCT01663402 · Phase 3
75 Q2W/Up150 Q2W
nasopharyngitis 7.5% (placebo 8.2%)
headache 6.5% (placebo 7.8%)
hypertension 5.9% (placebo 6.7%)
NCT02957682 · Phase 4 · registry result, not featured evidence
nasopharyngitis 26.2%
injection site reaction 6.8%
back pain 5.8%
NCT02984982 · Phase 4 · registry result, not featured evidence
75 mg Q2W/Up to 150 mg Q2W
urinary tract infection 5.5%
diarrhoea 5.1%
arthralgia 2.2%
NCT02642159 · Phase 4 · registry result, not featured evidence
150 mg Q2W
nasopharyngitis 22.2%
alanine aminotransferase increased 11.1%
aortic valve incompetence 11.1%
NCT03510715 · Phase 3 · registry result, not featured evidence
75 mg Q2W/up to 150 mg Q2W
aortic valve incompetence 22.2%
headache 22.2%
influenza 22.2%
NCT03510715 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.8%
myalgia 7.1%
headache 6.1%
NCT02476006 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 9.1%
arthralgia 6.1%
contusion 3%
NCT03415178 · Phase 3 · registry result, not featured evidence
urinary tract infection 6.1%
arthralgia 4.5%
contusion 1.5%
NCT03415178 · Phase 3 · registry result, not featured evidence
75 mg Q2W/up150 mg Q2W
upper respiratory tract infection 13.3%
accidental overdose 6.7%
NCT02715726 · Phase 3 · registry result, not featured evidence
150 mg Q2W
viral upper respiratory tract infection 15.1% (placebo 16.1%)
non-cardiac chest pain 7.5% (placebo 1.8%)
back pain 1.9% (placebo 0%)
NCT02584504 · Phase 3 · registry result, not featured evidence
150 mg Q4W
viral upper respiratory tract infection 14.8% (placebo 16.1%)
pharyngitis 5.6% (placebo 0%)
back pain 0% (placebo 0%)
NCT02584504 · Phase 3 · registry result, not featured evidence
150 mg Q4W/Up Q2W
viral upper respiratory tract infection 34.2% (placebo 16.1%)
fall 7% (placebo 5.4%)
back pain 5.1% (placebo 0%)
NCT02584504 · Phase 3 · registry result, not featured evidence
75 or 150 mg Q2W
viral upper respiratory tract infection 14.2%
upper respiratory tract infection 10.8%
influenza 9.3%
NCT01954394 · Phase 3 · registry result, not featured evidence
150 mg Q4W
viral upper respiratory tract infection 18.8% (placebo 5.2%)
back pain 14.6% (placebo 0%)
injection site reaction 14.6% (placebo 0%)
NCT02023879 · Phase 3 · registry result, not featured evidence
150 mg Q4W
viral upper respiratory tract infection 15.1% (placebo 5.2%)
fall 13.2% (placebo 1.7%)
diarrhoea 10.4% (placebo 3.4%)
NCT02023879 · Phase 3 · registry result, not featured evidence
150 mg Q4W
cough 17.6% (placebo 0%)
arthralgia 15.7% (placebo 6.9%)
osteoarthritis 15.7% (placebo 3.4%)
NCT02023879 · Phase 3 · registry result, not featured evidence
150 mg Q4W/Up150 mg Q2W
injection site reaction 13.8% (placebo 0%)
arthralgia 12.1% (placebo 6.9%)
headache 8.6% (placebo 6.9%)
NCT02023879 · Phase 3 · registry result, not featured evidence
75 mg Q2W/Up150 mg Q2W
headache 8.7% (placebo 6.9%)
viral upper respiratory tract infection 8.7% (placebo 5.2%)
muscle spasms 7.8% (placebo 0%)
NCT02023879 · Phase 3 · registry result, not featured evidence
75 mg/ up to 150 mg
myalgia 24.6%
nasopharyngitis 6.3%
upper respiratory tract infection 5.6%
NCT01709513 · Phase 3 · registry result, not featured evidence
75 mg Q2W/Up to 150 mg Q2W
nasopharyngitis 4.9% (placebo 5.3%)
NCT02585778 · Phase 3 · registry result, not featured evidence
75 mg Q2W/Up to 150 mg Q2W
dizziness 6.2% (placebo 2.9%)
nasopharyngitis 6.2% (placebo 3.9%)
diarrhoea 5.2% (placebo 1%)
NCT02289963 · Phase 3 · registry result, not featured evidence
75 mg/ Up to 150 mg Q2W
nasopharyngitis 45.5% (placebo 36.1%)
back pain 12.6% (placebo 5.6%)
injection site reaction 12.6% (placebo 4.2%)
NCT02107898 · Phase 3 · registry result, not featured evidence
75 mg/up to 150 mg + 10 mg
arthralgia 8.2%
nausea 6.1%
nasopharyngitis 4.1%
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
75 mg/up to 150 mg + 20 mg
myalgia 7.4%
upper respiratory tract infection 7.4%
injection site reaction 5.6%
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
75 mg/up to 150 mg + Atorvastatin 20 mg
muscle spasms 7%
back pain 5.3%
arthralgia 3.5%
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
75 mg/up to 150 mg + Atorvastatin 40 mg
back pain 8.5%
nasopharyngitis 8.5%
accidental overdose 6.4%
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
300 mg Q4W
acne 20%
diarrhoea 20%
influenza like illness 20%
NCT02890992 · Phase 2 · registry result, not featured evidence
150 mg Q4W
nasopharyngitis 20%
pyogenic granuloma 20%
upper respiratory tract infection 20%
NCT02890992 · Phase 2 · registry result, not featured evidence
150 mg Q4W
abdominal discomfort 16.7%
diarrhoea 16.7%
epistaxis 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
75 mg Q2W
ligament sprain 11.1%
nasopharyngitis 11.1%
abdominal pain 5.6%
NCT02890992 · Phase 2 · registry result, not featured evidence
75 mg Q2W
animal scratch 16.7%
arthropod bite 16.7%
blood follicle stimulating hormone decreased 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
75 mg Q4W
abdominal pain 16.7%
asthma 16.7%
depressed mood 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
50 mg Q2W
diarrhoea 33.3%
nasopharyngitis 33.3%
alcohol abuse 16.7%
NCT02890992 · Phase 2 · registry result, not featured evidence
40 mg Q2W
gastroenteritis viral 30%
ear infection 10%
headache 10%
NCT02890992 · Phase 2 · registry result, not featured evidence
40 mg Q2W
pharyngitis 25%
abdominal discomfort 0%
abdominal pain 0%
NCT02890992 · Phase 2 · registry result, not featured evidence
30 mg Q2W
ear infection 25%
epistaxis 25%
fall 25%
NCT02890992 · Phase 2 · registry result, not featured evidence
viral upper respiratory tract infection 40%
acne 20%
blood bilirubin increased 20%
NCT01604824 · Phase 2 · registry result, not featured evidence
gastroenteritis 33.3%
viral upper respiratory tract infection 33.3%
abdominal discomfort 16.7%
NCT01604824 · Phase 2 · registry result, not featured evidence
headache 28.6%
acne 14.3%
angina pectoris 14.3%
NCT01604824 · Phase 2 · registry result, not featured evidence
abdominal discomfort 20%
abdominal distension 20%
acne 20%
NCT01604824 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 28.3%
nasopharyngitis 23.9%
bronchitis 21.7%
NCT01576484 · Phase 2 · registry result, not featured evidence
n
nasopharyngitis 10.5% (placebo 9.6%)
upper respiratory tract infection 9.3% (placebo 6.3%)
influenza 7.5% (placebo 6.3%)
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 54 more results
bronchitis 12.5% (placebo 0%)
dyspepsia 12.5% (placebo 0%)
pain 12.5% (placebo 0%)
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
influenza 9.1% (placebo 0%)
upper respiratory tract infection 9.1% (placebo 6.3%)
gastroenteritis 6.1% (placebo 0%)
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
diabetes mellitus 8.4% (placebo 8%)
hypertension 7.8% (placebo 8.4%)
nasopharyngitis 7.7% (placebo 7.4%)
NCT01764633 · Phase 3
nasopharyngitis 10.3% (placebo 7.5%)
hypertension 6.2% (placebo 6.7%)
back pain 5.9% (placebo 3.6%)
NCT02207634 · Phase 3
Q2W
muscle spasms 2.7% (placebo 0%)
back pain 1.8% (placebo 0%)
diarrhoea 1.8% (placebo 0%)
NCT01763866 · Phase 3
QM
muscle spasms 3.6% (placebo 0%)
back pain 0.9% (placebo 0%)
dizziness 0.9% (placebo 0%)
NCT01763866 · Phase 3
Q2W
diarrhoea 3.7% (placebo 0%)
back pain 2.8% (placebo 0%)
muscle spasms 1.8% (placebo 0%)
NCT01763866 · Phase 3
QM
headache 2.7% (placebo 1.8%)
diarrhoea 1.8% (placebo 0%)
myalgia 1.8% (placebo 3.6%)
NCT01763866 · Phase 3
Q2W
back pain 1.8% (placebo 0%)
headache 1.8% (placebo 1.8%)
myalgia 0.9% (placebo 3.6%)
NCT01763866 · Phase 3
QM
headache 2.7% (placebo 1.8%)
back pain 0.9% (placebo 0%)
diarrhoea 0.9% (placebo 0%)
NCT01763866 · Phase 3
Q2W
muscle spasms 1.8% (placebo 0%)
back pain 0.9% (placebo 0%)
constipation 0.9% (placebo 5.4%)
NCT01763866 · Phase 3
QM
back pain 1.7% (placebo 0%)
diarrhoea 1.7% (placebo 0%)
dizziness 1.7% (placebo 0%)
NCT01763866 · Phase 3
Q2W
back pain 5.4% (placebo 0%)
dizziness 2.7% (placebo 0%)
muscle spasms 2.7% (placebo 0%)
NCT01763866 · Phase 3
QM
headache 4.3% (placebo 1.8%)
myalgia 2.6% (placebo 3.6%)
back pain 1.7% (placebo 0%)
NCT01763866 · Phase 3
Q2W
headache 3.3% (placebo 3.9%)
diarrhoea 2.6% (placebo 6.6%)
nasopharyngitis 2% (placebo 1.3%)
NCT01763827 · Phase 3
QM
diarrhoea 3.3% (placebo 6.6%)
headache 3.3% (placebo 3.9%)
nasopharyngitis 2% (placebo 1.3%)
NCT01763827 · Phase 3
Q2W
nasopharyngitis 7.3% (placebo 3.7%)
arthralgia 6.4% (placebo 1.9%)
headache 3.6% (placebo 1.9%)
NCT01763918 · Phase 3
QM
nasopharyngitis 10% (placebo 3.7%)
back pain 5.5% (placebo 0%)
headache 4.5% (placebo 1.9%)
NCT01763918 · Phase 3
420 mg QM
nasopharyngitis 11.5% (placebo 11.3%)
headache 10.6% (placebo 1.9%)
oropharyngeal pain 6.7% (placebo 0%)
NCT02392559 · Phase 3
upper respiratory tract infection 17%
headache 16%
influenza 16%
NCT01624142 · Phase 2/3
420 mg QM
nasopharyngitis 13.9%
headache 8.9%
influenza like illness 7.9%
NCT02624869 · Phase 3
420 mg QM
nasopharyngitis 16.3%
influenza like illness 10.2%
pyrexia 10.2%
NCT02624869 · Phase 3
420 mg QM
epistaxis 16.7%
abdominal pain upper 8.3%
acne 8.3%
NCT02624869 · Phase 3
allergic skin reaction 4.5%
elevated creatine kinase 1.5%
NCT04608474 · Phase 4 · registry result, not featured evidence
angina pectoris 3.3%
arthralgia 3.3%
arthritis 3.3%
NCT03403374 · Phase 4 · registry result, not featured evidence
runny nose 5.5%
NCT03689946 · Phase 3 · registry result, not featured evidence
hypertension 14.2% (placebo 12.9%)
bronchitis 6.9% (placebo 6.4%)
upper respiratory tract infection 6.5% (placebo 8.2%)
NCT02867813 · Phase 3 · registry result, not featured evidence
hypertension 7.5% (placebo 6.2%)
myalgia 6.3% (placebo 7.4%)
angina pectoris 5% (placebo 8.6%)
NCT03570697 · Phase 3 · registry result, not featured evidence
back pain 3.9% (placebo 2.5%)
influenza like illness 3.9% (placebo 2.5%)
diarrhoea 3.6% (placebo 4.5%)
NCT02833844 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.2%
arthralgia 4.3%
upper respiratory tract infection 4.2%
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.6%
hypertension 7.5%
upper respiratory tract infection 7.4%
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 12.6%
upper respiratory tract infection 8.3%
arthralgia 6.7%
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
Q2W
pharyngitis 15.8%
abdominal distension 10.5%
abdominal pain 5.3%
NCT02634580 · Phase 3 · registry result, not featured evidence
QM
nasopharyngitis 23.8%
hypertension 9.5%
injection site pain 9.5%
NCT02634580 · Phase 3 · registry result, not featured evidence
420 mg QM
influenza 10.8% (placebo 4.7%)
nasopharyngitis 9.2% (placebo 20.3%)
myalgia 7.7% (placebo 1.6%)
NCT02729025 · Phase 3 · registry result, not featured evidence
hypertension 6.4%
NCT02304484 · Phase 3 · registry result, not featured evidence
Q2W
diabetes mellitus 4.6% (placebo 1.2%)
nasopharyngitis 2.8% (placebo 3.7%)
upper respiratory tract infection 2.8% (placebo 3.7%)
NCT02662569 · Phase 3 · registry result, not featured evidence
QM
diabetes mellitus 4.5% (placebo 1.2%)
upper respiratory tract infection 3.9% (placebo 3.7%)
nasopharyngitis 3.3% (placebo 3.7%)
NCT02662569 · Phase 3 · registry result, not featured evidence
myalgia 13.8%
nasopharyngitis 9.7%
arthralgia 9%
NCT01984424 · Phase 3 · registry result, not featured evidence
hypertension 3.9% (placebo 0%)
diabetes mellitus 2.9% (placebo 3.5%)
diarrhoea 2.1% (placebo 2.8%)
NCT02739984 · Phase 3 · registry result, not featured evidence
myalgia 7% (placebo 5.6%)
chest pain 6.8% (placebo 5.4%)
hypertension 6% (placebo 7%)
NCT01813422 · Phase 3 · registry result, not featured evidence
headache 36.4% (placebo 9.5%)
influenza like illness 9.1% (placebo 0%)
nasopharyngitis 9.1% (placebo 4.8%)
NCT02189837 · Phase 3 · registry result, not featured evidence
headache 35% (placebo 9.5%)
myalgia 10% (placebo 4.8%)
nausea 10% (placebo 4.8%)
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
Q2W
nasopharyngitis 13.7% (placebo 9.6%)
diabetes mellitus 2% (placebo 0%)
gastroenteritis 0% (placebo 1.9%)
NCT01953328 · Phase 3 · registry result, not featured evidence
QM
nasopharyngitis 15.7% (placebo 9.6%)
gastroenteritis 5.9% (placebo 1.9%)
diabetes mellitus 3.9% (placebo 0%)
NCT01953328 · Phase 3 · registry result, not featured evidence
Q2W
nasopharyngitis 24% (placebo 9.6%)
diabetes mellitus 2% (placebo 0%)
gastroenteritis 2% (placebo 1.9%)
NCT01953328 · Phase 3 · registry result, not featured evidence
QM
nasopharyngitis 14% (placebo 9.6%)
gastroenteritis 4% (placebo 1.9%)
diabetes mellitus 0% (placebo 0%)
NCT01953328 · Phase 3 · registry result, not featured evidence
Q2W
myalgia 6.8%
muscle spasms 4.9%
nasopharyngitis 4.9%
NCT01763905 · Phase 3 · registry result, not featured evidence
QM
headache 11.8%
pain in extremity 11.8%
myalgia 8.8%
NCT01763905 · Phase 3 · registry result, not featured evidence
headache 2.7%
NCT01849497 · Phase 3 · registry result, not featured evidence
headache 5.3%
NCT01849497 · Phase 3 · registry result, not featured evidence
nasopharyngitis 28.7%
upper respiratory tract infection 14.4%
back pain 14.2%
NCT01439880 · Phase 2 · registry result, not featured evidence
nasopharyngitis 30.7%
arthralgia 15.8%
upper respiratory tract infection 14.3%
NCT01439880 · Phase 2 · registry result, not featured evidence
nasopharyngitis 16.8%
upper respiratory tract infection 8.2%
back pain 7%
NCT01439880 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dTrial phases differ: Phase 2/3 versus Phase 3.
  5. eTrial phases differ: Phase 3 versus Phase 4.
  6. fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  7. gAssessment timepoints differ: 80 weeks versus 168 weeks.
  8. hTrial phases differ: Phase 3 versus Phase 2.
  9. iPopulation context differs: registered conditions differ.
  10. jAssessment timepoints differ: 24 weeks versus 18 weeks.
  11. kAssessment timepoints differ: 78 weeks versus 36 weeks.
  12. lAssessment timepoints differ: 52 weeks versus 18 weeks.
  13. mPopulation comparability has not been reviewed for 82 of these studies.
  14. nPopulation comparability has not been reviewed for 60 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alirocumab

Total-C -33.3% (n=144) vs -1.9% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 36 more results
-35.8% (n=308) vs -0.8% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-37.4% (n=144) vs -1% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-32.9% (n=308) vs -0.1% (n=156) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-37.8% (n=1530) vs -0.3% (n=780) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-38.8% (n=1530) vs 0.2% (n=780) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-29.3% (n=467) vs -14.6% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-29.4% (n=467) vs -15.1% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-32.3% (n=58) vs 3% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-24.5% (n=58) vs 1.8% (n=57) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-31.4% (n=322) vs 7.3% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-28.3% (n=322) vs 4.1% (n=163) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-30.6% (n=166) vs 2.1% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-26.6% (n=166) vs 3.4% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-32.5% (n=37) vs -1.9% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-30% (n=76) vs -0.8% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-33.4% (n=37) vs -1% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-26.5% (n=76) vs -0.1% (n=156) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-34% (n=115) vs 3% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-32.6% (n=115) vs 1.8% (n=57) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-31.8% (n=126) vs -10.9% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-39.5% (n=143) vs 2% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-41.1% (n=143) vs -2.1% (n=72) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-28.9% (n=48) vs -8.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-20.6% (n=53) vs -8.3% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-29% (n=48) vs -8.9% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-19.4% (n=53) vs -8.9% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-27.1% (n=55) vs -4% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-33.6% (n=46) vs -4% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-29% (n=55) vs -6.5% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-29% (n=46) vs -6.5% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-29.6% (n=1058) vs -0.3% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-31.8% (n=1058) vs 1.5% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-29.6% (n=1058) vs 1.1% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-29% (n=1058) vs 1.1% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-26.5% (n=1058) vs 1.8% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
-32.7% (n=126) vs -11.6% (n=122) Ezetimibe @ 12wk75/ up to 150
NCT01709513 · Phase 3 · registry result, not featured evidence
LDL-C Goal Attainment 80.7% (n=1530) vs 8.5% (n=780) placebo @ 24wk150 mg Q2W
responder rate · % of participants
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 25 more results
82.8% (n=1523) vs 8.5% (n=777) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
85.2% (n=54) vs 14.3% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
96.2% (n=53) vs 14.3% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
85.2% (n=54) vs 10.8% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
96.2% (n=53) vs 10.8% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
63.9% (n=58) vs 1.8% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
67.7% (n=57) vs 1.8% (n=56) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
72.2% (n=322) vs 2.4% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
73% (n=321) vs 2.4% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
81.4% (n=166) vs 11.3% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
82.1% (n=166) vs 11.6% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
70.3% (n=115) vs 1.8% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
72.7% (n=115) vs 1.8% (n=56) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
41.9% (n=126) vs 4.4% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
51.2% (n=123) vs 5.6% (n=118) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
96.7% (n=143) vs 10.2% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
97.9% (n=143) vs 10.6% (n=71) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
84.9% (n=48) vs 45% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
66.7% (n=53) vs 45% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
86.4% (n=48) vs 47% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
70.4% (n=51) vs 47% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
87.2% (n=55) vs 34.5% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
84.6% (n=46) vs 34.5% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
91.2% (n=52) vs 37.8% (n=52) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
90% (n=46) vs 37.8% (n=52) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
Fasting Triglycerides -15.6% (n=1530) vs 1.8% (n=780) placebo @ 24wk150 mg Q2W
percent change · % of baseline
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
-16.7% (n=1530) vs 1.2% (n=780) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
Apo A1 5.2% (n=138) vs -1.4% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 59 more results
5.5% (n=292) vs 2.9% (n=146) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
4.6% (n=138) vs -1.8% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
6% (n=292) vs 2.7% (n=146) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
4% (n=1468) vs 1.2% (n=753) placebo @ 24wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
4.6% (n=1468) vs 0.6% (n=753) placebo @ 12wk150 mg Q2W
NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
3.3% (n=185) vs -2.5% (n=96) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
3.8% (n=185) vs -1.8% (n=96) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
4.2% (n=41) vs 0% (n=21) placebo @ 6wk150 mg Q2W
NCT02326220 · Phase 3
7.8% (n=41) vs -0.7% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
5% (n=452) vs -1.3% (n=228) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
1.5% (n=467) vs -2.9% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
4.7% (n=48) vs -0.6% (n=46) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
2.3% (n=48) vs -2.2% (n=46) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
5% (n=45) vs 1.4% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
5% (n=45) vs 1.4% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
6.8% (n=54) vs 2.9% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
9.1% (n=53) vs 2.9% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
10% (n=58) vs 3.4% (n=56) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
7.6% (n=58) vs 2.6% (n=56) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
5% (n=309) vs 0.3% (n=160) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
2.9% (n=309) vs 0.1% (n=160) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
2.8% (n=163) vs -1.6% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
0.4% (n=163) vs -1.9% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
3.1% (n=34) vs -1.4% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
6.5% (n=75) vs 2.9% (n=146) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
2.4% (n=34) vs -1.8% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
6.1% (n=75) vs 2.7% (n=146) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
3.2% (n=398) vs -0.2% (n=203) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
3.7% (n=398) vs 1.1% (n=203) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
8.2% (n=112) vs 3.4% (n=56) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
5.9% (n=112) vs 2.6% (n=56) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
4.8% (n=122) vs 2.9% (n=116) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
5.5% (n=122) vs 3.9% (n=116) Ezetimibe @ 12wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
4.5% (n=96) vs 3.2% (n=100) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
4.5% (n=96) vs 1.5% (n=100) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
1.4% (n=141) vs -2.6% (n=71) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
1.5% (n=141) vs -4.8% (n=71) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
6.7% (n=44) vs 5.4% (n=44) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
6.7% (n=49) vs 5.4% (n=44) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
4.3% (n=44) vs 4% (n=44) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
9.1% (n=49) vs 4% (n=44) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
7.6% (n=53) vs 1.2% (n=51) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
5.8% (n=42) vs 1.2% (n=51) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
5.4% (n=53) vs -0.8% (n=51) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
9.4% (n=42) vs -0.8% (n=51) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
1% (n=47) vs -0.1% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
4.4% (n=49) vs -0.1% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-1.7% (n=47) vs -0.1% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
5% (n=49) vs -0.1% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-1.7% (n=47) vs -0.1% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
5% (n=49) vs -0.1% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
1% (n=47) vs -0.1% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
4.4% (n=49) vs -0.1% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
1.7% (n=1058) vs -1.3% (n=1051) placebo @ 12wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
6.1% (n=1058) vs 2.9% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
7.7% (n=1058) vs 4.7% (n=1051) placebo @ 48wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
7.8% (n=1058) vs 4.4% (n=1051) placebo @ 72wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
7.5% (n=1058) vs 4.2% (n=1051) placebo @ 96wk75 Q2W/Up150 Q2W
NCT02957682 · Phase 4 · registry result, not featured evidence
11.75% (n=92) vs 4.61% (n=88) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
Fasting TG -13.4% (n=144) vs -1.5% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
percent change · % of baseline
NCT01926782 · Phase 3
show 53 more results
-15.2% (n=308) vs -0.1% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-12.3% (n=144) vs 1.8% (n=71) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-13.1% (n=308) vs 0.5% (n=156) placebo @ 12wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
-6% (n=205) vs -5.4% (n=106) placebo @ 24wk75/150 mg Q2W
NCT01644175 · Phase 3
-11.3% (n=205) vs 3% (n=106) placebo @ 12wk75/150 mg Q2W
NCT01644175 · Phase 3
-13% (n=467) vs -12.8% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-13% (n=467) vs -12.8% (n=240) Ezetimibe @ 12wk75 /up to 150 mg Q2W
NCT01644188 · Phase 3
-11.9% (n=52) vs -10.8% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-12.2% (n=52) vs -2.3% (n=51) Ezetimibe @ 12wk75/Up to 150 mg Q2W
NCT01644474 · Phase 3
-7.4% (n=45) vs 3.9% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-7.4% (n=45) vs 3.9% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-0.6% (n=54) vs -6.4% (n=56) placebo @ 12wk150 mg Q4W
NCT02584504 · Phase 3 · registry result, not featured evidence
-18% (n=53) vs -6.4% (n=56) placebo @ 12wk150 mg Q2W
NCT02584504 · Phase 3 · registry result, not featured evidence
-9.2% (n=58) vs 1.1% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-3% (n=58) vs 2.1% (n=57) placebo @ 12wk150 mg Q4W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-9.6% (n=322) vs 6.3% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-8% (n=322) vs 1.7% (n=163) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT01623115 · Phase 3
-10.4% (n=166) vs 0.5% (n=81) placebo @ 24wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-8.1% (n=166) vs 0.6% (n=81) placebo @ 12wk75 mg/up to 150 mg
NCT01709500 · Phase 3
-9.8% (n=37) vs -1.5% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-6.7% (n=76) vs -0.1% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-18.3% (n=37) vs 1.8% (n=71) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-7.3% (n=76) vs 0.5% (n=156) placebo @ 12wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
-13% (n=273) vs -8.8% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02642159 · Phase 4 · registry result, not featured evidence
-14.462% (n=403) vs -14.409% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-9.965% (n=403) vs -13.585% (n=208) Ezetimibe @ 12wk75 mg Q2W/up to 150 mg Q2W
NCT02715726 · Phase 3 · registry result, not featured evidence
-10.6% (n=115) vs 1.1% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-11.3% (n=115) vs 2.1% (n=57) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02023879 · Phase 3 · registry result, not featured evidence
-9.3% (n=126) vs -3.6% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-8% (n=126) vs -9.4% (n=122) Ezetimibe @ 12wk75 mg/ up to 150 mg
NCT01709513 · Phase 3 · registry result, not featured evidence
-13.6% (n=49) vs 1.9% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-5.7% (n=287) vs 1.9% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02585778 · Phase 3 · registry result, not featured evidence
-8.143% (n=97) vs -3.627% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-6.999% (n=97) vs 2.113% (n=102) placebo @ 12wk75 mg Q2W/Up to 150 mg Q2W
NCT02289963 · Phase 3 · registry result, not featured evidence
-15.3% (n=143) vs 6.7% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-13.1% (n=143) vs 2.4% (n=72) placebo @ 12wk75 mg/Up to 150 mg Q2W
NCT02107898 · Phase 3 · registry result, not featured evidence
-11.2% (n=48) vs -1.8% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-8.7% (n=53) vs -1.8% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-14% (n=48) vs 8.1% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 10 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-10.1% (n=53) vs 8.1% (n=48) Rosuvastatin @ 12wk75 mg/up to 150 mg + 20 mg
NCT01730053 · Phase 3 · registry result, not featured evidence · combination
-12% (n=55) vs -6.7% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-19.1% (n=46) vs -6.7% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-12.4% (n=55) vs -4.7% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 20 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
-12.1% (n=46) vs -4.7% (n=53) Atorvastatin @ 12wk75 mg/up to 150 mg + Atorvastatin 40 mg
NCT01730040 · Phase 3 · registry result, not featured evidence · combination
11.9% (n=49) vs 7.7% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-6.8% (n=52) vs 7.7% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-2.2% (n=49) vs 6.5% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-0.3% (n=52) vs 6.5% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
-2.2% (n=49) vs 6.5% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
-0.3% (n=52) vs 6.5% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
11.9% (n=49) vs 7.7% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
-6.8% (n=52) vs 7.7% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
-18.37% (n=93) vs -8.85% (n=89) Standard of Care @ 36wk
NCT02984982 · Phase 4 · registry result, not featured evidence
LDL-C Target Achievement 78.9% (n=144) vs 9.4% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
responder rate · % of participants
NCT01926782 · Phase 3
show 7 more results
85.2% (n=308) vs 22.2% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
88.6% (n=141) vs 11.3% (n=70) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
89.5% (n=302) vs 22.5% (n=151) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W
NCT01926782 · Phase 3
84.9% (n=37) vs 9.4% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
82.5% (n=76) vs 22.2% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
93% (n=37) vs 11.3% (n=70) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
86.4% (n=75) vs 22.5% (n=151) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W
NCT01926782 · Phase 3
Apheresis Treatment 0.128 vs 0.806 placebo Treatments @ 18wk150 mg Q2W
absolute change · Treatments
NCT02326220 · Phase 3
show 1 more result
0.165 vs 0.774 placebo Treatments @ 18wk150 mg Q2W
NCT02326220 · Phase 3
LDL-C 30 Reduction 95.1% (n=41) vs 4.8% (n=21) placebo @ 6wk150 mg Q2W
responder rate · % of participants
NCT02326220 · Phase 3
show 10 more results
65.9% (n=41) vs 0% (n=21) placebo @ 18wk150 mg Q2W
NCT02326220 · Phase 3
57.1% (n=45) vs 4.2% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
65.8% (n=49) vs 0.8% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
70.8% (n=52) vs 0.8% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
66.7% (n=49) vs 4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
72.5% (n=52) vs 4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
65.8% (n=49) vs 0.8% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
70.8% (n=52) vs 0.8% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
66.7% (n=49) vs 4% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
72.5% (n=52) vs 4% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
W-BQ22 0.91 vs -1.43 placebo score @ 18wk150 mg Q2W
absolute change · score
NCT02326220 · Phase 3
LDL-C Less Than 100 88.1% (n=52) vs 32.2% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W
responder rate · % of participants
NCT01644474 · Phase 3
LDL-C 15% Reduction 61.9% (n=45) vs 12.5% (n=24) placebo @ 12wk150 mg SC Q2W
responder rate · % of participants
NCT03156621 · Phase 3
LDL-C 50% Reduction 26.7% (n=45) vs 0% (n=24) placebo @ 12wk150 mg SC Q2W
responder rate · % of participants
NCT03156621 · Phase 3
show 8 more results
25.2% (n=49) vs 0% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
31.9% (n=52) vs 0% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
21.6% (n=49) vs 0% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
32.4% (n=52) vs 0% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3
25.2% (n=49) vs 0% (n=25) placebo @ 12wkQ2W
NCT03510884 · Phase 3
31.9% (n=52) vs 0% (n=25) placebo @ 12wkQ4W
NCT03510884 · Phase 3
21.6% (n=49) vs 0% (n=25) placebo @ 24wkQ2W
NCT03510884 · Phase 3
32.4% (n=52) vs 0% (n=25) placebo @ 24wkQ4W
NCT03510884 · Phase 3

+ 69 further endpoints in the CSV export.

Evolocumab

LDL-C 82.3% (n=599) vs 6.4% (n=302) placebo @ 52wk
responder rate · % of participants
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
VLDL-C 2.74% (n=599) vs 31.89% (n=302) placebo @ 52wk
percent change · % of baseline
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 47 more results
-6.85% (n=110) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-11.77% (n=110) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-8.96% (n=109) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-6.38% (n=110) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-12.22% (n=113) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-7.25% (n=115) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-9.09% (n=111) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-15.05% (n=112) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-14.57% (n=112) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-16.5% (n=115) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-6.16% (n=110) vs 8.32% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-11.73% (n=110) vs 8.32% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-9.69% (n=109) vs 8.32% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-1.06% (n=110) vs 8.32% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-8.2% (n=113) vs 8.32% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-6.28% (n=115) vs 8.32% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-6.1% (n=111) vs 8.32% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-9.95% (n=112) vs 8.32% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-14.83% (n=112) vs 8.32% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-15.86% (n=115) vs 8.32% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-8.4% (n=153) vs -3.81% (n=76) placeboQ2W
NCT01763827 · Phase 3
-16.17% (n=153) vs -3.81% (n=76) placeboQM
NCT01763827 · Phase 3
-9.52% (n=153) vs -1.58% (n=76) placebo @ 12wkQ2W
NCT01763827 · Phase 3
-16.33% (n=153) vs -1.58% (n=76) placebo @ 12wkQM
NCT01763827 · Phase 3
-13.97% (n=110) vs 8.66% (n=54) placeboQ2W
NCT01763918 · Phase 3
-9.2% (n=110) vs 8.66% (n=54) placeboQM
NCT01763918 · Phase 3
-17.25% (n=110) vs 3.73% (n=54) placebo @ 12wkQ2W
NCT01763918 · Phase 3
-5.06% (n=110) vs 3.73% (n=54) placebo @ 12wkQM
NCT01763918 · Phase 3
-9.81% (n=284) vs 12.34% (n=141) placebo @ 24wk
NCT02833844 · Phase 3 · registry result, not featured evidence
-17.55% (n=325) vs 9.63% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-16.09% (n=332) vs 9.63% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-6.81% (n=145) vs -2.15% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-3.9% (n=145) vs -2.66% (n=73) Ezetimibe @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
-13.64% (n=280) vs 3.42% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
-10.31% (n=280) vs 3.02% (n=141) placebo @ 12wk
NCT02739984 · Phase 3 · registry result, not featured evidence
-25.29% (n=50) vs 2.57% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-19.55% (n=50) vs 2.57% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-19.41% (n=51) vs 2.57% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-17.2% (n=51) vs 2.57% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-24.33% (n=50) vs 4.09% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-17.89% (n=50) vs 4.09% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-18.08% (n=51) vs 4.09% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-15.18% (n=51) vs 4.09% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-7.6% (n=103) vs -5.76% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-6.46% (n=102) vs -5.76% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
-6.16% (n=103) vs -5.49% (n=51) Ezetimibe @ 12wkQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-2.18% (n=102) vs -5.49% (n=51) Ezetimibe @ 12wkQM
NCT01763905 · Phase 3 · registry result, not featured evidence
MACE 3-point Composite 1.65% (n=13784) vs 1.86% (n=13780) placebo @ 26wk
event count · % of participants
NCT01764633 · Phase 3
show 5 more results
3.1% (n=13784) vs 3.68% (n=13780) placebo @ 52wk
NCT01764633 · Phase 3
4.29% (n=13784) vs 5.18% (n=13780) placebo @ 78wk
NCT01764633 · Phase 3
5.47% (n=13784) vs 6.83% (n=13780) placebo @ 104wk
NCT01764633 · Phase 3
6.66% (n=13784) vs 8.31% (n=13780) placebo @ 130wk
NCT01764633 · Phase 3
7.9% (n=13784) vs 9.93% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
MI 1.06% (n=13784) vs 1.14% (n=13780) placebo @ 26wk
responder rate · % of participants
NCT01764633 · Phase 3
show 5 more results
1.9% (n=13784) vs 2.39% (n=13780) placebo @ 52wk
NCT01764633 · Phase 3
2.55% (n=13784) vs 3.33% (n=13780) placebo @ 78wk
NCT01764633 · Phase 3
3.21% (n=13784) vs 4.3% (n=13780) placebo @ 104wk
NCT01764633 · Phase 3
3.83% (n=13784) vs 5.25% (n=13780) placebo @ 130wk
NCT01764633 · Phase 3
4.41% (n=13784) vs 6.28% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
CV Death or HF Hospitalization Composite 0.64% (n=13784) vs 0.79% (n=13780) placebo @ 26wk
responder rate · % of participants
NCT01764633 · Phase 3
show 5 more results
1.29% (n=13784) vs 1.35% (n=13780) placebo @ 52wk
NCT01764633 · Phase 3
1.99% (n=13784) vs 1.99% (n=13780) placebo @ 78wk
NCT01764633 · Phase 3
2.64% (n=13784) vs 2.7% (n=13780) placebo @ 104wk
NCT01764633 · Phase 3
3.31% (n=13784) vs 3.45% (n=13780) placebo @ 130wk
NCT01764633 · Phase 3
4.13% (n=13784) vs 4.03% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
CANTAB SWM Between-errors 0.0691 vs 0.1024 placebo score
absolute change · score
NCT02207634 · Phase 3
CANTAB PAL Total Errors 0.0873 vs 0.1098 placebo score
absolute change · score
NCT02207634 · Phase 3
CANTAB RTI Median Reaction Time -0.0575 vs 0.0153 placebo score
absolute change · score
NCT02207634 · Phase 3
TC/HDL -34.96% (n=104) vs -4.66% (n=53) placebo @ 24wk420 mg QM
ratio to baseline · % of baseline
NCT02392559 · Phase 3
show 46 more results
-40.44% (n=110) vs 5.96% (n=56) placeboQ2W
NCT01763866 · Phase 3
-42.45% (n=110) vs 5.96% (n=56) placeboQM
NCT01763866 · Phase 3
-40.22% (n=109) vs 5.96% (n=56) placeboQ2W
NCT01763866 · Phase 3
-40.43% (n=110) vs 5.96% (n=56) placeboQM
NCT01763866 · Phase 3
-39.33% (n=113) vs 5.96% (n=56) placeboQ2W
NCT01763866 · Phase 3
-42% (n=115) vs 5.96% (n=56) placeboQM
NCT01763866 · Phase 3
-36.04% (n=111) vs 5.96% (n=56) placeboQ2W
NCT01763866 · Phase 3
-38.62% (n=112) vs 5.96% (n=56) placeboQM
NCT01763866 · Phase 3
-47.2% (n=112) vs 5.96% (n=56) placeboQ2W
NCT01763866 · Phase 3
-43.17% (n=115) vs 5.96% (n=56) placeboQM
NCT01763866 · Phase 3
-40.74% (n=110) vs 6.09% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-40.07% (n=110) vs 6.09% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-40.79% (n=109) vs 6.09% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-36.25% (n=110) vs 6.09% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-38.57% (n=113) vs 6.09% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-39.26% (n=115) vs 6.09% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-35.17% (n=111) vs 6.09% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-32.3% (n=112) vs 6.09% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-47.24% (n=112) vs 6.09% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-39.47% (n=115) vs 6.09% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-38.49% (n=153) vs 0.44% (n=76) placeboQ2W
NCT01763827 · Phase 3
-39.41% (n=153) vs 0.44% (n=76) placeboQM
NCT01763827 · Phase 3
-38.45% (n=153) vs 1.18% (n=76) placebo @ 12wkQ2W
NCT01763827 · Phase 3
-37.65% (n=153) vs 1.18% (n=76) placebo @ 12wkQM
NCT01763827 · Phase 3
-45.74% (n=110) vs 0.86% (n=54) placeboQ2W
NCT01763918 · Phase 3
-45.02% (n=110) vs 0.86% (n=54) placeboQM
NCT01763918 · Phase 3
-45.95% (n=110) vs 0.12% (n=54) placebo @ 12wkQ2W
NCT01763918 · Phase 3
-38.32% (n=110) vs 0.12% (n=54) placebo @ 12wkQM
NCT01763918 · Phase 3
-41.06% (n=325) vs 3.03% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-45.7% (n=332) vs 3.03% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-40.72% (n=325) vs 3.22% (n=164) placebo @ 12wkQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-41.78% (n=332) vs 3.22% (n=164) placebo @ 12wkQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-41.39% (n=145) vs -11.48% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-40.04% (n=145) vs -12.84% (n=173) Ezetimibe @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
-51% (n=50) vs 3.77% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-48.71% (n=50) vs 3.77% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-49.79% (n=51) vs 3.77% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-48.11% (n=51) vs 3.77% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-50.72% (n=50) vs 4.73% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-46.62% (n=50) vs 4.73% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-49.52% (n=51) vs 4.73% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-44.61% (n=51) vs 4.73% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-40.83% (n=103) vs -13.44% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-41.14% (n=102) vs -13.44% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
-40.42% (n=103) vs -14.13% (n=51) Ezetimibe @ 12wkQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-38.57% (n=102) vs -14.13% (n=51) Ezetimibe @ 12wkQM
NCT01763905 · Phase 3 · registry result, not featured evidence
ApoB/ApoA-1 -37.02% (n=104) vs -0.63% (n=53) placebo @ 24wk420 mg QM
ratio to baseline · % of baseline
NCT02392559 · Phase 3
show 46 more results
-53.56% (n=110) vs 6.41% (n=56) placeboQ2W
NCT01763866 · Phase 3
-53.33% (n=110) vs 6.41% (n=56) placeboQM
NCT01763866 · Phase 3
-52.43% (n=109) vs 6.41% (n=56) placeboQ2W
NCT01763866 · Phase 3
-56.2% (n=110) vs 6.41% (n=56) placeboQM
NCT01763866 · Phase 3
-52.46% (n=113) vs 6.41% (n=56) placeboQ2W
NCT01763866 · Phase 3
-56.66% (n=115) vs 6.41% (n=56) placeboQM
NCT01763866 · Phase 3
-48.47% (n=111) vs 6.41% (n=56) placeboQ2W
NCT01763866 · Phase 3
-54.17% (n=112) vs 6.41% (n=56) placeboQM
NCT01763866 · Phase 3
-58.76% (n=112) vs 6.41% (n=56) placeboQ2W
NCT01763866 · Phase 3
-57.47% (n=115) vs 6.41% (n=56) placeboQM
NCT01763866 · Phase 3
-54.17% (n=110) vs 6.13% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-49.65% (n=110) vs 6.13% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-53.59% (n=109) vs 6.13% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-50.76% (n=110) vs 6.13% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-52.97% (n=113) vs 6.13% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-52.13% (n=115) vs 6.13% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-47.53% (n=111) vs 6.13% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-45.65% (n=112) vs 6.13% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-59.53% (n=112) vs 6.13% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-52.56% (n=115) vs 6.13% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-48.12% (n=153) vs 1.01% (n=76) placeboQ2W
NCT01763827 · Phase 3
-51.1% (n=153) vs 1.01% (n=76) placeboQM
NCT01763827 · Phase 3
-48.45% (n=153) vs 1.12% (n=76) placebo @ 12wkQ2W
NCT01763827 · Phase 3
-48.26% (n=153) vs 1.12% (n=76) placebo @ 12wkQM
NCT01763827 · Phase 3
-52.39% (n=110) vs 0.78% (n=54) placeboQ2W
NCT01763918 · Phase 3
-53.91% (n=110) vs 0.78% (n=54) placeboQM
NCT01763918 · Phase 3
-52.74% (n=110) vs 1.54% (n=54) placebo @ 12wkQ2W
NCT01763918 · Phase 3
-45.31% (n=110) vs 1.54% (n=54) placebo @ 12wkQM
NCT01763918 · Phase 3
-55.6% (n=325) vs 2.6% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-57.75% (n=332) vs 2.6% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-54.98% (n=325) vs 3.23% (n=164) placebo @ 12wkQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-51.8% (n=332) vs 3.23% (n=164) placebo @ 12wkQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-45.99% (n=145) vs -11.86% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-44.6% (n=145) vs -12.62% (n=73) Ezetimibe @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
-66.41% (n=50) vs 0.06% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-61.55% (n=50) vs 0.06% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-65.97% (n=51) vs 0.06% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-65.72% (n=51) vs 0.06% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-67.59% (n=50) vs 0.71% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-58.45% (n=50) vs 0.71% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-65.11% (n=51) vs 0.71% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-60.56% (n=51) vs 0.71% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-47.86% (n=103) vs -13% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-48.31% (n=102) vs -13% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
-47.66% (n=103) vs -13.14% (n=51) Ezetimibe @ 12wkQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-45.51% (n=102) vs -13.14% (n=51) Ezetimibe @ 12wkQM
NCT01763905 · Phase 3 · registry result, not featured evidence
TC/HDL -28.78% (n=40) @ 80wk420 mg QM
ratio to baseline · % of baseline
No placebo or comparator arm
NCT02624869 · Phase 3
show 25 more results
-28.32% (n=88) @ 80wk420 mg QM
NCT02624869 · Phase 3
3.71% (n=11) @ 80wk420 mg QM
NCT02624869 · Phase 3
-21.32% (n=106) @ 4wk
NCT01624142 · Phase 2/3
-23.25% (n=106) @ 6wk
NCT01624142 · Phase 2/3
-23.93% (n=106) @ 8wk
NCT01624142 · Phase 2/3
-21.2% (n=106) @ 12wk
NCT01624142 · Phase 2/3
-24.01% (n=106) @ 16wk
NCT01624142 · Phase 2/3
-24.69% (n=106) @ 20wk
NCT01624142 · Phase 2/3
-23.53% (n=106) @ 24wk
NCT01624142 · Phase 2/3
-27.16% (n=106) @ 36wk
NCT01624142 · Phase 2/3
-26.54% (n=106) @ 48wk
NCT01624142 · Phase 2/3
-22.8% (n=106) @ 60wk
NCT01624142 · Phase 2/3
-24.79% (n=106) @ 72wk
NCT01624142 · Phase 2/3
-22.62% (n=106) @ 84wk
NCT01624142 · Phase 2/3
-23% (n=106) @ 96wk
NCT01624142 · Phase 2/3
-25.03% (n=106) @ 108wk
NCT01624142 · Phase 2/3
-25.4% (n=106) @ 120wk
NCT01624142 · Phase 2/3
-25.66% (n=106) @ 132wk
NCT01624142 · Phase 2/3
-27.79% (n=106) @ 144wk
NCT01624142 · Phase 2/3
-25.52% (n=106) @ 156wk
NCT01624142 · Phase 2/3
-26.3% (n=106) @ 168wk
NCT01624142 · Phase 2/3
-29.53% (n=106) @ 180wk
NCT01624142 · Phase 2/3
-27.79% (n=106) @ 192wk
NCT01624142 · Phase 2/3
-27.32% (n=106) @ 204wk
NCT01624142 · Phase 2/3
-30.92% (n=106) @ 216wk
NCT01624142 · Phase 2/3
ApoB/ApoA-1 -31% (n=44) @ 80wk420 mg QM
ratio to baseline · % of baseline
No placebo or comparator arm
NCT02624869 · Phase 3
show 25 more results
-29.89% (n=87) @ 80wk420 mg QM
NCT02624869 · Phase 3
-2.96% (n=11) @ 80wk420 mg QM
NCT02624869 · Phase 3
-23.06% (n=106) @ 4wk
NCT01624142 · Phase 2/3
-21.38% (n=106) @ 6wk
NCT01624142 · Phase 2/3
-21.53% (n=106) @ 8wk
NCT01624142 · Phase 2/3
-16.67% (n=106) @ 12wk
NCT01624142 · Phase 2/3
-22.52% (n=106) @ 16wk
NCT01624142 · Phase 2/3
-25.41% (n=106) @ 20wk
NCT01624142 · Phase 2/3
-22.97% (n=106) @ 24wk
NCT01624142 · Phase 2/3
-26.86% (n=106) @ 36wk
NCT01624142 · Phase 2/3
-25.96% (n=106) @ 48wk
NCT01624142 · Phase 2/3
-24.31% (n=106) @ 60wk
NCT01624142 · Phase 2/3
-23.63% (n=106) @ 72wk
NCT01624142 · Phase 2/3
-24.09% (n=106) @ 84wk
NCT01624142 · Phase 2/3
-24.75% (n=106) @ 96wk
NCT01624142 · Phase 2/3
-26.03% (n=106) @ 108wk
NCT01624142 · Phase 2/3
-26.45% (n=106) @ 120wk
NCT01624142 · Phase 2/3
-24.26% (n=106) @ 132wk
NCT01624142 · Phase 2/3
-28.09% (n=106) @ 144wk
NCT01624142 · Phase 2/3
-27.21% (n=106) @ 156wk
NCT01624142 · Phase 2/3
-32.16% (n=106) @ 168wk
NCT01624142 · Phase 2/3
-28.7% (n=106) @ 180wk
NCT01624142 · Phase 2/3
-27.5% (n=106) @ 192wk
NCT01624142 · Phase 2/3
-28.04% (n=106) @ 204wk
NCT01624142 · Phase 2/3
-28.37% (n=106) @ 216wk
NCT01624142 · Phase 2/3

+ 13 further endpoints in the CSV export.

Homozygous Familial Hypercholesterolemia

Shared mechanism: PCSK9 · full Homozygous Familial Hypercholesterolemia pipeline

Alirocumab · Praluent

Marketed by Regeneron Pharmaceuticals and partners

Approved in Homozygous Familial Hypercholesterolemiamonoclonal antibody
Partial signal

NCT03156621 · Phase 3 · completed

The trial randomized 69 participants 2:1 to triple-blinded alirocumab or matching placebo, and its primary LDL-cholesterol endpoint was met, with a statistically significant difference favoring alirocumab (p<0.0001). The record does not report a power or sample-size calculation, so the study provides meaningful but limited evidence despite its strong randomized and blinded design.

Reported efficacy

Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand): Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) (Baseline to Week 12): Alirocumab 150 mg SC Q2W -26.9 Percentage of change (Standard Error 4.6) vs Placebo in DBTP 8.6 Percentage of change (Standard Error 6.3) (met)

Result source: NCT03156621

Evolocumab · Repatha

Marketed by Amgen

Approved in Homozygous Familial Hypercholesterolemiamonoclonal antibody
Reliable signal

NCT01588496 · Phase 2/3 · completed

The randomized, quadruple-blind, placebo-controlled Part B (n=49) used a hard, regulator-accepted endpoint (LDL-C change from baseline) and the primary comparison was statistically significant and strongly favored evolocumab (LS mean difference -30.93%, 95% CI -43.86 to -18.00, p<0.001). Part A was an open-label single-arm pilot, but the grade is based on the randomized placebo-controlled Part B, which provides strong evidence for the drug.

Reported efficacy

Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12); Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12): Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001 (met)

Result source: NCT01588496

Results for Homozygous Familial Hypercholesterolemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Alirocumab: 8 of 8 rows · Evolocumab: 7 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlirocumab
Rows use multiple source trials
Evolocumab
Apo B
percent change · % of baseline
-22.5% (n=45) vs 7.2% (n=24) placebo @ 12wk150 mg SC Q2Wa,b,c,d
NCT03156621 · Phase 3
show 1 more dose
-22.5% (n=45) vs 7.2% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
-19.17% (n=33) vs 3.97% (n=16) placebo @ 12wka,b,c,d
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
show 1 more dose
-20.24% (n=33) vs 2.65% (n=16) placebo
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
Apo B
percent change · % of baseline
No placebo or comparator arm
-4.2% (n=18) @ 12wkb,c,d
NCT03510715 · Phase 3 · registry result, not featured evidence
-14.9% (n=8) @ 12wkb,c,d
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
1 other source trial
-6% (n=29) @ 12wk
NCT03403374 · Phase 4 · registry result, not featured evidence
Lp(a
percent change · % of baseline
-19.6% (n=45) vs 8.8% (n=24) placebo @ 12wk150 mg SC Q2Wb,c,d
NCT03156621 · Phase 3
-9.4% (n=33) vs 2.43% (n=16) placebo @ 12wka,b,c,d
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
show 1 more dose
-12.71% (n=33) vs -1.43% (n=16) placebo
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
Non-HDL-C
percent change · % of baseline
No placebo or comparator arm
-3.9% (n=18) @ 12wkb,c,d
NCT03510715 · Phase 3 · registry result, not featured evidence
-16.6% (n=8) @ 12wkb,c,d
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
Dropout rate
0%150 mg SC Q2We
NCT03156621 · Phase 3
show 4 more results
—150 Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
0%Part A: Evolocumabf
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
show 4 more results
—Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
3.3%
NCT03403374 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
—150 mg SC Q2We
NCT03156621 · Phase 3
show 4 more results
—150 Q2W
NCT03156621 · Phase 3
—150 Q2W
NCT03156621 · Phase 3
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
—Part A: Evolocumabf
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
show 4 more results
—Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—
NCT03403374 · Phase 4 · registry result, not featured evidence
Serious AEs
—150 mg SC Q2We
NCT03156621 · Phase 3
show 4 more results
0%150 Q2W
NCT03156621 · Phase 3
2.2%150 Q2W
NCT03156621 · Phase 3
0%150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
11.1%75 mg Q2W/up to 150 mg Q2W
NCT03510715 · Phase 3 · registry result, not featured evidence
—Part A: Evolocumabf
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
show 4 more results
0%Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
6.7%
NCT03403374 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
150 Q2We
diarrhoea 6.7% (placebo 0%)
headache 4.4% (placebo 8.3%)
nasopharyngitis 4.4% (placebo 0%)
NCT03156621 · Phase 3
show 3 more results
150 Q2W
nasopharyngitis 6.7% (placebo 0%)
diarrhoea 2.2% (placebo 0%)
headache 2.2% (placebo 8.3%)
NCT03156621 · Phase 3
150 mg Q2W
nasopharyngitis 22.2%
alanine aminotransferase increased 11.1%
aortic valve incompetence 11.1%
NCT03510715 · Phase 3 · registry result, not featured evidence
75 mg Q2W/up to 150 mg Q2W
aortic valve incompetence 22.2%
headache 22.2%
influenza 22.2%
NCT03510715 · Phase 3 · registry result, not featured evidence
f
bronchitis 12.5% (placebo 0%)
dyspepsia 12.5% (placebo 0%)
pain 12.5% (placebo 0%)
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
show 2 more results
influenza 9.1% (placebo 0%)
upper respiratory tract infection 9.1% (placebo 6.3%)
gastroenteritis 6.1% (placebo 0%)
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
angina pectoris 3.3%
arthralgia 3.3%
arthritis 3.3%
NCT03403374 · Phase 4 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2/3 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation comparability has not been reviewed for these studies.
  6. fPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alirocumab

Non-HDL-C -24.8% (n=45) vs 8% (n=24) placebo @ 12wk150 mg SC Q2W
percent change · % of baseline
NCT03156621 · Phase 3
show 1 more result
-24.8% (n=45) vs 8% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
Total Cholesterol -19.8% (n=45) vs 6.6% (n=24) placebo @ 12wk150 mg SC Q2W
percent change · % of baseline
NCT03156621 · Phase 3
show 1 more result
-19.8% (n=45) vs 6.6% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
HDL-C 6.3% (n=45) vs 2.7% (n=24) placebo @ 12wk150 mg SC Q2W
percent change · % of baseline
NCT03156621 · Phase 3
show 1 more result
6.3% (n=45) vs 2.7% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
Fasting TG -7.4% (n=45) vs 3.9% (n=24) placebo @ 12wk150 mg SC Q2W
percent change · % of baseline
NCT03156621 · Phase 3
show 1 more result
-7.4% (n=45) vs 3.9% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
Apo A1 5% (n=45) vs 1.4% (n=24) placebo @ 12wk150 mg SC Q2W
percent change · % of baseline
NCT03156621 · Phase 3
show 1 more result
5% (n=45) vs 1.4% (n=24) placebo @ 12wk150 mg SC Q2W
NCT03156621 · Phase 3
ApoB/ApoA-1 -0.3 vs 0 placebo ratio @ 12wk150 mg SC Q2W
ratio to baseline · ratio
NCT03156621 · Phase 3
LDL-C -4.1% (n=18) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT03510715 · Phase 3 · registry result, not featured evidence
show 2 more results
-10.1% (n=18) @ 24wk
NCT03510715 · Phase 3 · registry result, not featured evidence
4.2% (n=18) @ 48wk
NCT03510715 · Phase 3 · registry result, not featured evidence
Total Cholesterol -1.9% (n=18) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT03510715 · Phase 3 · registry result, not featured evidence
show 2 more results
-6.3% (n=18) @ 24wk
NCT03510715 · Phase 3 · registry result, not featured evidence
5.5% (n=18) @ 48wk
NCT03510715 · Phase 3 · registry result, not featured evidence
Lp(a 7.4% (n=18) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT03510715 · Phase 3 · registry result, not featured evidence
show 2 more results
-5.2% (n=18) @ 24wk
NCT03510715 · Phase 3 · registry result, not featured evidence
-6.4% (n=18) @ 48wk
NCT03510715 · Phase 3 · registry result, not featured evidence
HDL-C 13% (n=18) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT03510715 · Phase 3 · registry result, not featured evidence
show 2 more results
8.9% (n=18) @ 24wk
NCT03510715 · Phase 3 · registry result, not featured evidence
10.1% (n=18) @ 48wk
NCT03510715 · Phase 3 · registry result, not featured evidence
Fasting TG 2.8% (n=18) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT03510715 · Phase 3 · registry result, not featured evidence
show 2 more results
5.2% (n=18) @ 24wk
NCT03510715 · Phase 3 · registry result, not featured evidence
10% (n=18) @ 48wk
NCT03510715 · Phase 3 · registry result, not featured evidence
Apo A1 11.3% (n=18) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT03510715 · Phase 3 · registry result, not featured evidence
show 2 more results
14.6% (n=18) @ 24wk
NCT03510715 · Phase 3 · registry result, not featured evidence
11.3% (n=18) @ 48wk
NCT03510715 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alirocumab's landscape · Evolocumab's landscape